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ABSTRACT 
 
Mycobacterium tuberculosis (Mtb) replicates within the human macrophages and we investigated the 
activating effects of retinoic acid (RA) and vitamin D3 (VD) on macrophages in relation to the 
viability of Mtb. A combination of these vitamins (RAVD) enhanced the receptors on THP-1 
macrophage (Mannose receptor and DC-SIGN) that increased mycobacterial uptake but inhibited the 
subsequent intracellular growth of Mtb by inducing reactive oxygen species (ROS) and autophagy. 
RAVD also enhanced antigen presenting and homing receptors in THPs that suggested an activated 
phenotype for THPs following RAVD treatment. RAVD mediated activation was also associated 
with a marked phenotypic change in Mtb infected THPs that fused with adjacent cells to form 
multinucleate giant cells (MNGCs). Typically MNGCs occurred over 30 days of in vitro culture and 
contained non-replicating persisting Mtb for as long as 60 days in culture. We propose that the 
RAVD mediated inhibition of replicating Mtb leading to persistence of non-replicating Mtb within 
THPs may provide a novel human macrophage model simulating formation of MNGCs in human 
lungs.  
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INTRODUCTION 
 
 
 
 
 
2 
 
Mycobacterium tuberculosis 
Tuberculosis (TB), a disease that has afflicted the human race for millennia, still causes 1.3 
million deaths per year among HIV-negative patients(1).  The etiologic agent, Mycobacterium 
tuberculosis (Mtb) is unique among bacterial pathogens in being able to survive in vivo for years before 
reactivation to cause disease. The clinical manifestations of TB represent a complex interaction between 
the bacteria, Mtb, and the human host immune response.  Although, Mtb can parasitize, survive and 
grow within macrophages only a minority of people exposed to infection progress to disease.  It is 
widely believed that protection against the disease requires immune-competent host reactions that 
activate T-helper 1-type (Th1) immune responses(2). 
Inhalation of aerosol droplets containing Mtb is known to be the natural route for pulmonary TB 
infection.  Following Mtb infection of alveolar macrophages, an intense local inflammatory response 
involving a series of innate immune and Th1 dominant adaptive pathways is induced.  These responses 
lead to the recruitment of macrophages, lymphocytes and dendritic cells to the site of infection leading 
to the formation of a granuloma, the signature histopathological feature of tuberculosis(3).   Granuloma 
formation is thought sufficient to contain the infection and prevent active disease in most healthy 
individuals, but is unable to completely eradicate the infection(4).  Instead, the infection is kept at a 
latent state where the host is asymptomatic but still has Mtb within their lungs that can re-activate into 
active infection upon compromise of the host immune defense.  One-third of the world’s population is 
estimated to be currently infected with TB, where most those infected are in a latent state of 
infection(1), understanding the host and bacterial interactions during granuloma formation is necessary 
for disease management. 
 
Vitamin D and Tuberculosis  
For over a century, the administration of Vitamin D3 (VD) has been considered beneficial for 
the treatment tuberculosis disease. Even before Robert Koch discovered the causative agent of TB as 
Mycobacterium tuberculosis (Mtb), foods high in this vitamin, such as Cod Liver Oil(5) and milk, along 
with exposure to sunlight was the recommended treatment course during the pre-chemotherapy era of 
tuberculosis disease.   Current clinical studies show increasing roles for VD in tuberculosis; where lower 
serum VD levels(6, 7) and polymorphisms in the Vitamin D Receptor (VDR) gene were found 
associated with increased susceptibility.(8, 9) 
 In conjunction with these epidemiological studies, new roles for VD in immune responses have 
been discovered in recent years.  VD, in the form of cholecalciferol, used in skeletal processes must 
travel to the liver to be converted into 25-dihydroxyvitamin D (25(OH)VD3), then to the kidneys to be 
converted into its metabolically active form, 1,25-dihydroxyvitamin D3  (1,25(OH)2VD3).(10)  Unlike 
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the skeletal system that depends on shuttling VD metabolites around the body, immune cells have been 
found to express their own enzymes to metabolize VD (cholecalciferol) into 1,25(OH)2VD3.  
Macrophages and dendritic cells (DC) both express, CYP27A1, the enzyme needed to convert serum 
VD into 25(OH)VD3, and CYP27B1, the enzyme that further converts it to active 1,25(OH)2VD3(10, 
11).   
 During Mtb infection, macrophages become a target for VD by increasing expression of 
VDR.(12) Expression of VDR promotes chemotaxis(13), phagocytosis(14), antigen processing(15), 
superoxide synthesis(14, 16) and production of pro-inflammatory cytokines, like interleukin 1-beta (IL-
1β)(17)and tumor necrosis factor alpha (TNF-α )(18), to eliminate the infection.  Recently, VD has been 
shown to regulate the expression of LL-37(19), an antimicrobial peptide of the cathelicidin family with 
the dual ability of modulating the immune response by  recruiting monocytes, T-lympocytes and 
neutrophils to the site of infection(20). 
Unlike macrophages and DCs, activated T-cells only express CYP27B1 and are therefore, more 
dependent on liver, macrophage or dendritic cell conversion of VD into 1,25(OH)2VD3(21).  The 
difference between VD metabolism in T-cells and macrophages also extends to their functional response 
to 1,25(OH)2VD3.  While 1,25(OH)2VD3 initially stimulates a pro-inflammatory response in 
macrophages, the reverse is true for T-cells.  The presence of 1,25(OH)2VD3 leads to inhibition of T-cell 
differentiation, proliferation, and Th1 cell immunoactivity(22).  This inverse relation of VD function in 
macrophages and T-cells has led to the idea that VD is a “self-regulatory” molecule with essential roles 
in controlling the longevity of the inflammatory response. 
 Interestingly, 1,25(OH)2VD3 has been shown to have an autocrine effect on macrophages. 
Macrophages activated with interferon-gamma (IFN-γ) will secrete active 1,25(OH)2VD3 to negatively 
feedback onto itself and suppress the ongoing Th1 immune responses(23).   To date, there are no studies 
conducted to determine if the THP-1 macrophage cell line exhibit VD metabolising enzymes, however, 
macrophages derived from human patients do express CYP27A1 and CYP27B1(11). Therefore, for our 
studies, we choose to use the more cost-effective and inactive form of VD (cholecalciferol) instead of 
1,25(OH)2VD3 that would also allow us to lessen the effects of accidental suppression of the 
inflammatory response. 
 
Retinoic Acid and Tuberculosis  
 Vitamin A is mostly associated with a role in vision, maintaining the integument and the 
reproductive system(24).  However, its active metabolite, retinoic acid, has been found to affect multiple 
processes in the immune system.  In the tissues, dietary vitamin A, in the form of β-carotene, all-trans-
retinol or retinyl esters must be broken down by ubiquitously expressed enzymes such as, alcohol 
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dehydrogenases or short-chain dehydrogenase reductases, into all-trans-retinal(25, 26). Retinal 
dehydrogenases (RALDHs), the tightly controlled key enzymes in Vitamin A metabolism, converts all-
trans-retinal into its active metabolite all-trans-retinoic acid (retinoic acid; RA)(25, 26). Excess RA is 
converted into retinyl esters and stored in the liver or excreted out of the urine or bile ducts(25, 26). 
Currently, the only immune cells to exhibit RALDHs are dendritic cells(27) that also have the ability to 
store and excrete RA to immunomodulate surrounding cells(28). 
 Prior to the discovery of antibiotics, the use of retinoic acid (RA) as an “anti-infective” agent 
was greatly debated for the treatment of infectious disease(29). During that period, as Vitamin D was 
being heralded as a treatment for tuberculosis, the role of RA was often overlooked even though it was 
usually found in equal or greater quantity in cod liver oil and milk(29).  To date, there are no clinical 
trials on the sole effects of RA as a therapeutic or preventative therapy for tuberculosis.  However, there 
is a correlation between RA serum levels and tuberculosis, where human studies have shown that 
tuberculosis patients exhibit decreased RA in their serum that return to normal once the infection has 
cleared(30).  RA, given at a 10-5M dose in cultured human macrophages immediately after infection, 
was shown to slow or stop intracellular Mtb growth(31).  However, a lower, more physiologically 
relevant dose (10-7M)(32) given before infection showed the same protective effect(31).   
Although it is still unclear as to the role of RA in human tuberculosis, several studies have tried 
to elucidate its general effects on the immune system during infection.   RA has been shown to have the 
ability to modulate lymphocyte and macrophage populations(33), increase mRNA transcription of TNF-
α, IL-1ß, inducible nitric oxide synthetase and IFN-γ(33), which led to a decrease of TB severity and 
viable bacilli(33, 34).  Interestingly, a study in viruses shows a link between autophagy and RA 
signaling pathways where the Atg12-Atg5 complex, a key regulator of autophagy, associates with the 
signaling molecules retinoic acid-inducible gene I (RIG-I) and interferon-beta promoter stimulator 1 
(IPS-1)(35). Complexing of these molecules leads to a down-regulation of Type 1 interferons that are 
normally induced by viral infections and suppression of the innate anti-viral response(35).  To date, no 
studies on the effects of RA inducing autophagy on anti-bacterial response in macrophages have been 
conducted, although it has been clearly demonstrated that autophagosome-lysosome pathway plays an 
essential role in eliminating Mtb infection(36). 
 
Retinoic Acid and Vitamin D 
In the early 1930s, clinical trials using cod liver oil(37), or combinations of Vitamin A & D(38) 
showed promise in reducing morbidity and mortality in tuberculosis in children. However, with the 
discovery of antibiotics, therapeutic studies on vitamins A & D waned(29).  Presently, with the 
emergence of multi-drug resistant strains of tuberculosis on the rise, research into the effects of vitamin 
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A and D as therapeutic adjuvants has emerged.  Unlike the pre-antibiotic era, most current clinical 
studies focus on the sole effects of one vitamin instead of combination therapy(39) that may be 
misleading since cross-talk between the two cell signaling pathways is likely(10, 40). 
Both Vitamins A and D exert their cellular effects via nuclear receptors, which when activated, 
will bind to promoters of their response genes to facilitate transcription.  Once VD is converted into its 
metabolite, 1,25(OH)2VD3, it will complex with the nuclear vitamin D receptor (VDR) that 
heterodimerizes with nuclear receptors of the retinoic X receptor (RXR) family(10).  Retinoic acid, 
metabolized from Vitamin A, will also heterodimer with RXR via its retinoic acid receptor (RAR)(10).  
The common ability for RXR to bind to both VDR and RAR can lead to the possibility of cross-talk 
within their response elements(40) that may lead to a synergistic(41) or antagonistic(42)effect 
depending on the response element being evaluated.  
In the case of tuberculosis, Vitamin A and D have shown to work synergistically to induce a 
decrease in tryptophan-aspartate-containing coat protein (TACO) gene transcription(43).  Phagocytosis 
of Mtb leads to the recruitment of TACO onto the phagosomal membrane that prevents maturation and 
degradation of the pathogen.  Therefore, a combined treatment of Vitamin A and D allowed greater 
phagosome maturation to occur in Mtb infected macrophages that, in turn, led to a decrease in pathogen 
viability(41). 
 
Effects of Retionoic Acid and Vitamin D on THP-1 Macrophages 
Given the importance of Vitamin A and D on the immune system, their classic role as 
preventive and therapeutic treatments in tuberculosis, and their common signaling systems, studies on 
the dual effects of Vitamin A and D are surprisingly lacking in tuberculosis.  Therefore, we initiated our 
study on the activating effects of retinoic acid (RA) and vitamin D3 (VD) on macrophages in relation to 
Mtb infection.   
Due to the difficulty of obtaining alveolar macrophages we utilized a human monocytoid cell 
line, THP-1(44), which is commonly substituted for in vitro studies of macrophage responses to Mtb 
infection.  THPs however need to be activated before they differentiate into a macrophage-like cells 
(45).  Phorbol myristate acetate (PMA) is the most common chemical activator for THPs(46), inducing 
adherence, upregulation of phagocytic receptors and an overall macrophage-like state. However, PMA, 
in vivo, is toxic for humans and is not a substance endogenously produced in the host.  Unlike PMA, all-
trans retinoic acid (RA)(47) and Vitamin D3 (VD)(48) are THP activating agents that are basic 
components of a healthy diet and have been shown to be linked to immune responses against Mtb 
infection(31, 34, 49).  We therefore examined the effects of PMA and RAVD on the phenotype and 
function of THP cells to develop an in vitro model that is closer to Mtb infected human alveolar 
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macrophages.  During these studies, we observed differing effects of PMA and RAVD on THP cells.  
PMA activated THPs (PMA-THPs) allowed enhanced growth of Mtb as observed before. However, 
RAVD activated THPs (RAVD-THPs) inhibited Mtb and with the addition of physiologically relevant, 
increasing doses of RA and VD, sustained bacteriostasis occurred. Furthermore, only in RAVD-THPs, 
Mtb induced the generation and gradual evolution of various morphotypes of macrophages to represent 
epithelioid cells, binucleate and MNGCs, culminating in syncytia. Thus, for the first time, it appears 
possible to study a chronic interaction between a slowly replicating mycobacterium that also has the 
unique ability to remain in a persistent stage in macrophages. 
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CHAPTER 2 
 
TREATMENT OF THP-1 CELLS WITH RETINOIC ACID AND 
VITAMIN D LEADS TO AN INCREASED PHENOTYPIC DIFFERENTIATION COMPARED 
TO PHORBOL MYRISTATE ACETATE MEDIATED ACTIVATION 
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INTRODUCTION 
 
Activation of THP-1 cells 
Macrophages have a wide range of plasma membrane receptors that allow them to sense 
pathogens and interact with their environment. THP-1 cells (THPs) are a monocytic cell line that has 
minimal receptor expression before activation that after exposure to PMA, a classic activator for THPs, 
will adhere and up-regulate phagocytic receptors to yield an overall macrophage-like state.  However, 
PMA, in vivo, is toxic for humans while, all-trans retinoic acid (RA)(47) and Vitamin D3 (VD)(48) are 
basic components of a healthy diet, endogenously metabolized by the host to affect immune response 
against Mtb infection(31, 34, 49).  We therefore examined the effects of PMA and RAVD on the up-
regulation of receptors important in tuberculosis. 
 
Macrophage Receptors Involved in Tuberculosis Pathogenesis 
Uptake or Binding to Mycobacteria (CD14, CD44, DC-SIGN, MMR) 
Macrophages have the ability to recognize, respond and phagocytose Mtb they encounter in 
their environment.  We focused on four receptors, CD14, CD44, Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), and Macrophage Mannose Receptor (MMR), 
which has been shown to be important in binding, signaling and uptake of Mtb during infection.   
  CD14, is a cell surface glycosylphosphatidyl-inositol anchored glycoprotein and has no 
transmembrane domain and therefore cannot induce signaling within the cell(50).  However, it was 
found to induce signaling cascades during the detection of lipopolysaccharide (LPS) by acting as a co-
receptor for Toll-like Receptor 4 (TLR-4)(50).  In tuberculosis, CD14 can interact with several different 
Mtb surface components such as, lipoarabinomannan(51), trehalose 6,6'-dimycolate (TDM)(52), 
LprA(53), LprG(53), or LpqH(53), to mediate uptake of the bacilli and stimulate release of pro-
inflammatory cytokines(51-53).   Interestingly, several epidemiological studies show that polymorphism 
in the 159 amino acid sequence of CD14 is a risk factor for the development of tuberculosis (54, 55). 
 Similar to CD14, CD44 mediates mycobacterial phagocytosis and induces protective immunity 
against Mtb(56).  CD44 is a transmembrane glycoprotein receptor for hyaluronic acid and is found on a 
plethora of immune cells where it is involved in lymphocyte activation, recirculation and homing, 
hematopoiesis, and tumor metastasis(57).   CD44 has been shown to be important during granuloma 
formation in lungs infected with Mtb(56) and furthermore, CD44-/- mice were more susceptible to TB 
infection and showed a decrease in macrophage and lymphocyte recruitment to the site of infection(56).    
DC-SIGN is a transmembrane protein with a calcium dependent (C-type) lectin domain that is 
normally expressed on interstitial dendritic cells and tissue specific macrophages, including alveolar 
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macrophages, within the human body(58).  In undifferentiated THP cells, it is usually found at low 
levels. However, THPs activated with PMA or other differentiating agents, can express high levels of 
DC-SIGN(58).  This is in contrast to other in vitro monocytic cells lines such as, U937, HL-60, Mono-
Mac6, and K562 cells, which do not express DC-SIGN regardless of activation(58).  The lectin domain 
of DC-SIGN has been found to recognize a large array of sugar moieties on a number of pathogens, 
including Mycobacterium tuberculosis(59, 60), HIV(61), Helicobacter pylori(62), Candida(63), Ebola 
virus(64), Schistosoma mansoni(62) and Leishmania amastigotes(65). During Mtb infection, DC-SIGN 
is known to bind to mannosylated lipoarabinomannan (ManLAM), a lipoglycan component of the 
mycobacterial cell wall, which mediates bacterial recognition and uptake into the cell(66).  Similar to 
CD44, DC-SIGN polymorphisms in the gene promoter region are associated with tuberculosis (67).   
MMR is the major receptor involved in Mtb uptake for macrophages.  Similar to DC-SIGN, 
MMR binds to the ManLAM component of the mycobacterial cell wall that initiates internalization of 
the pathogen(68).  It has been theorized that phagocytosis facilitated by MMR can lead to targeting of 
Mtb to specific compartments.   Thus, MMR mediated internalization of ManLAM leads to endocytic 
compartments tagged with CD1b, that may facilitate antigen presentation to T-cells(69).  The beneficial 
role of MMR in control of tuberculosis is still debated since uptake of mycobacterial glycolipids by 
MMR has been shown to decrease phagosome maturation rate in macrophages(70).  It is interesting to 
note that during multinucleated giant cell formation in macrophages, MMR expression levels are 
elevated indicating that it may be essential to cell fusion events(71).  Alternatively, MMR may perform 
scavenging function(72). 
 
Cross talk with T cells (HLA-DR, CD1d, CD80, CD86) 
 Along with phagocytosis and the degradation of internalized pathogens, macrophages have the 
ability to present processed antigens to T-cells to amplify immune responses in the host.  Activation of 
T-cells is mediated by two signals that are provided by antigen presenting cells, such as macrophages, to 
generate adoptive immunity.  The first signal requires the presentation of antigen by MHC molecules 
(such as HLA-DR or CD1d) on the macrophage cell surface that binds to the T-cell receptor (TCR)(73).  
The second signal requires no antigen presentation but involves the binding of co-stimulatory molecules 
(such as CD80 and CD86) to their respective T-cell ligands, such as CD28 and CTLA-4(73).  We 
wished to determine if activation with RAVD would increase antigen presenting receptors, such as 
HLA-DR and CD1d along with co-receptors CD80 and CD86 that may allow better crosstalk between 
infected macrophages and T-cells. 
 HLA-DR (Human Leukocyte Antigens – DR) is a major histocompatibility complex class II 
(MHC-II) cell surface receptor, found on macrophages, which presents processed peptide antigens to 
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CD4+ T-cells.  During infection, HLA-DR surface expression increases that elicit cytokine responses 
from activated T-cells.  To combat this effect, Mtb has evolved mechanisms to reduce HLA-DR 
expression and thereby reduce inflammation that can eliminate the infection(74, 75).  Although there are 
many subtypes of class II HLA molecules, such as HLA-DP,DM, DOA,DOB & DQ, only HLA-DR has 
been shown in epidemiological studies to be related to susceptibility to tuberculosis(76).  Therefore, we 
were interested in determining if RAVD activation of macrophages would allow for a greater surface 
expression of HLA-DR. 
CD1d (Cluster of Differentiation-1d) are class I antigen-presenting glycoproteins located on the 
surface of macrophages that present processed foreign lipid antigens to a unique subset of T-cells called 
Natural Killer T (NKT) cells(77).  Once activated, NKT cells can rapidly produce cytokines that can 
activate innate and adaptive immune responses in the host(77). Mtb has been shown to subvert CD1d 
expression in dendritic cells by phosphorylating host cell p38 mitogen-activated protein kinase, thereby 
preventing mycobacterial lipids from being presented to T-cells(78).   
CD80 and CD86 are two molecules that are located on the surface of monocytes and act 
together to stimulate T-cell responses to antigens.  Accordingly, CD80 and CD86 have been shown to 
be important for the control of chronic Mtb infections. Thus, T-cell mediated granuloma formation was 
reduced in CD80/CD86 double knock-out mice(79).  Both molecules have been shown to increase in 
surface expression during the maturation process of monocytes into dendritic cell and macrophages(80-
82).  Therefore, we tested PMA and RAVD treated cells to determine if surface expression of the two 
molecules differed depending on the activator used. 
 
Homing and Migration Receptors (CD195 and CD184) 
 Trafficking of lymphocytes throughout the body allows for the presentation of antigens to 
immune cell rich organs such as the spleen and lymph nodes, which greatly facilitates immune 
responses against foreign invaders. For macrophages to be able to directly travel to specific organs in 
the host, they must express receptors that allow them to “home” to a specific location.  These homing 
receptors are specific for addressins, which are extracellular proteins of the endothelium. The binding of 
these homing receptors to their specific addressin directs the macrophage to the infection or 
inflammation site. 
 CD195, also known as chemokine receptor type 5 (CCR5), is a G-linked integral protein that 
has been shown to bind a number of chemokines such as RANTES, MIP-1α and MIP-1β(83).  
Expression of CD195 is detected in monocytes and T lymphocytes where they participate in activation 
and migration of leukocytes(83).  CD184, also known as CXCR4 chemokine receptor, binds stromal-
derived factor-1 (SDF-1 or CXCL12) that allows it to home to the bone marrow.  Along with their roles 
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in homing macrophages to specific sites inside the host body, both CD195 and CD184, are important 
co-receptors in mediating HIV entry into host cells(84).   Since the synergistic interactions of TB and 
HIV-1 center on the role of macrophages in the disease process, we wished to evaluate macrophage 
receptor expression of CD195 and CD184, two cell surface receptors important to both Mtb and HIV 
infections(84). 
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RESULTS 
 
Phorbol myristyl acetate (PMA) and a combination of Retinoic acid (RA) and Vitamin 
D3 (VD) induce a different surface receptor expression and bacterial uptake in THPs 
 
Differential Receptor Expression in Activated Macrophages 
Macrophages express several types of receptors with different functional consequences.  Some 
mediate uptake of Mtb (CD44, DC-SIGN), while others help a cross talk with T cells (HLA-DR, CD1d, 
CD80, CD86). Others like chemokine receptors CD195 and CD184 enable homing to infected sites 
while some like CD14 bind mycobacterial cell wall components altering cytokine signaling. RAVD and 
PMA had differential effects on receptor expression analyzed using flow cytometry.  Receptors were 
generally up regulated in THPs activated with RAVD compared to PMA. In an experiment repeated 
three times with similar results, THPs were tested naïve or treated with various concentrations of PMA 
or RAVD, infected with H37Rv, and then stained for CD11c after 24 hours (Figure 1A-C; Tables 1A-
C). Expression of antigen presenting molecules HLA-DR, CD1d, CD80 and CD86 was increased. 
CD184 and CD195 were also increased in RAVD versus PMA activated THPs along with the TLR-4 
co-receptor, CD14.  Such receptors may make THPs more responsive to chemokines enabling homing, 
infiltration and bacterial detection. CD44 has been implicated as a receptor for Mtb but showed no 
difference between RAVD and PMA activated cells (56). However, DC-SIGN increased in RAVD-
THPs that is important for capture of Mtb and antigen presentation to T cells (60).   
We also evaluated receptor expression in THPs treated with RA alone, VD alone and in 
combination (RAVD).  We observed that RA and VD were separately able to activate THPs although, 
maximal differentiation occurred in the synergistic presence of the two vitamins.  An example of the 
combined effect on DC-SIGN is shown in Figure 1D.   
 
PMA and RAVD have differential effects on the uptake of Mycobacterium tuberculosis (Mtb) in 
THPs   
Receptor expression in activated THPs suggested that the optimal dose of RAVD was 1 μM 
(1000 nM) and PMA was 10ng/mL (16 nM) and the optimal activation time was 72 hrs.  All further 
studies utilized this optimized dose and activation. RAVD-THPs showed enhanced uptake of 
mannosylated-BSA-FITC, a classic probe used to measure macrophage mannose receptor (MMR) 
function, before infection with Mtb (Figure 2A). Furthermore, only RAVD-THPs maintained mannose 
receptor expression even after Mtb infection (Figure 2B).  
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MMR was then evaluated to determine if the difference observed in receptor expression would 
lead to a functional disparity in PMA and RAVD treated THPs.  Since MMR is a receptor for 
mycobacterial glycolipids that allows for Mtb uptake (85), we assessed whether activated THPs differed 
in their internalized Mtb populations.  Activated THPs were infected with Mtb H37Rv (MOI of 10) and 
evaluated for uptake of mycobacteria.  Microscopic analysis of Ziehl-Neelsen stained Mtb in fixed PMA 
and RAVD treated THPs demonstrated a differential uptake of Mtb (Figure 3).  RAVD activated THPs 
were better able to engulf Mtb, where over 75% of the macrophage population had internalized at least 
one mycobacterium, while only 60% of the PMA activated THPs demonstrated internalized Mtb. This 
data correlated with the increased expression of mycobacterial up-take receptors (Figure 1A, 2A-B).
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Figure 1A.  Flow cytometric analysis of receptors involved in the uptake of mycobacteria in 
human THP-1 macrophages activated with either phorbol myristate acetate (PMA) or retinoic 
acid and vitamin D (RAVD).  
THPs were activated with varying doses (as indicated) of PMA or a mix of RAVD for 72 hrs and were 
stained for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using Cellquest 
software. Mean Fluorescence Intensity (MFIs) from triplicate experiments were calculated to show 
significance as indicated (* indicates MFI significantly increased between PMA and RAVD activated 
THP-1 cells, paired t-test). 
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CD44 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) --- *** 44.94 44.94±0 
RAVD (10nM) --- 21.38 42.08 31.73±10.35 
 Medium Dose  
PMA (10ng/mL) --- 27.48 35.31 31.40±3.92 
RAVD (100nM) --- *** 44.23 44.23±0 
 High Dose  
PMA (50ng/mL) --- 25.39 28.69 27.04±1.65 
RAVD (1000nM) --- 20.48 36.90 28.69±8.20 
Paired t-test p = 0.5642       
CD14 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 41.08 21.48 38.69 33.75±6.17 
RAVD (10nM) 38.01 31.15 39.61 36.26±2.60 
 Medium Dose  
PMA (10ng/mL) 46.09 24.92 35.31 35.44±6.11 
RAVD (100nM) 49.81 30.83 39.61 40.08±5.48 
 High Dose  
PMA (50ng/mL) 40.15 26.43 33.80 33.46±3.96 
RAVD (1000nM) 47.45 32.15 38.26 39.29±4.45 
Paired t-test p = 0.0078 
DC-SIGN Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 47.31 17.47 39.27 34.68±8.91 
RAVD (10nM) 42.31 32.71 46.06 40.36±3.98 
 Medium Dose  
PMA (10ng/mL) 39.58 24.98 39.82 34.79±4.91 
RAVD (100nM) 46.17 33.94 44.82 41.64±3.87 
 High Dose  
PMA (50ng/mL) 37.97 28.52 31.86 32.78±2.77 
RAVD (1000nM) 46.47 32.64 45.03 41.38±4.39 
Paired t-test p = 0.0065       ---   No data 
         ***Incalculable data 
 
Table 1A.  Tabulated data of mean fluorescence intensity (MFIs) depicted in the flow cytometric 
analysis of uptake or binding receptors to mycobacteria on PMA or RAVD activated human 
THP-1 macrophages.   
THPs were activated with varying doses (as indicated) of PMA or RAVD for 72 hrs and were stained 
for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using Cellquest 
software. MFIs from triplicate experiments were tabulated and analyzed using a paired t-test to show 
significance at p<0.05   (*** indicates samples with no Geo Mean calculated during flow cytometry 
acquisition). 
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Figure 1B.  Flow cytometric analysis of chemokine receptors in human THP-1 macrophages 
activated with either PMA or RAVD.  
THPs were activated with varying doses (as indicated) of PMA or a mix of RAVD for 72 hrs and were 
stained for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using Cellquest 
software. MFIs from triplicate experiments were calculated to show significance as indicated (* 
indicates MFI significantly increased between PMA and RAVD activated THP-1 cells, paired t-test).  
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CD184 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) --- *** 41.02 41.02±0 
RAVD (10nM) --- 34.74 46.81 40.78±6.04 
 Medium Dose  
PMA (10ng/mL) --- 25.40 37.60 31.50±6.10 
RAVD (100nM) --- 36.97 49.40 43.19±6.22 
 High Dose  
PMA (50ng/mL) --- 27.95 31.15 29.55±1.60 
RAVD (1000nM) --- 36.94 48.19 42.57±5.63 
Paired t-test p = 0.0040      
CD195 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 45.07 30.10 44.69 39.95±4.93 
RAVD (10nM) 42.36 34.14 50.34 42.28±4.68 
 Medium Dose  
PMA (10ng/mL) 45.11 25.89 44.05 38.35±6.24 
RAVD (100nM) 39.60 36.05 50.79 42.15±4.44 
 High Dose  
PMA (50ng/mL) 45.73 25.00 30.25 33.66±6.22 
RAVD (1000nM) 51.11 36.36 51.38 46.28±4.96 
Paired t-test p = 0.0431       ---   No data 
         ***Incalculable data 
 
 
Table 1B.  Tabulated data of MFIs depicted in the flow cytometric analysis of chemokine 
receptors on PMA or RAVD activated human THP-1 macrophages. 
THPs were activated with varying doses (as indicated) of PMA or a mix of RA and VD for 72 hrs and 
were stained for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using 
Cellquest software. MFIs from triplicate experiments were tabulated and analyzed using a paired t-test 
to show significance at p<0.05 (*** indicates samples with no Geo Mean calculated during flow 
cytometry acquisition). 
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Figure 1C.  Flow cytometric analysis of antigen presenting receptors in human THP-1 
macrophages activated with either PMA or RAVD.  
THPs were activated with varying doses (as indicated) of PMA or a mix of RAVD for 72 hrs and were 
stained for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using Cellquest 
software. MFIs from triplicate experiments were calculated to show significance as indicated (* 
indicates MFI significantly increased between PMA and RAVD activated THP-1 cells, paired t-test).  
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CD80 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 34.73 13.26 13.63 20.54±7.10 
RAVD (10nM) 35.02 14.34 14.98 21.45±6.79 
 Medium Dose  
PMA (10ng/mL) 32.66 13.49 13.73 19.96±6.35 
RAVD (100nM) 39.10 14.30 14.57 22.66±8.22 
 High Dose  
PMA (50ng/mL) 30.37 13.66 14.13 19.39±5.49 
RAVD (1000nM) 33.94 14.04 14.49 20.82±6.56 
Paired t-test p = 0.0392   
CD86 Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 31.25 15.71 16.84 21.27±5.00 
RAVD (10nM) 35.57 29.03 18.31 27.64±5.03 
 Medium Dose  
PMA (10ng/mL) 33.98 15.95 17.80 22.58±5.73 
RAVD (100nM) 34.16 17.56 18.21 23.31±5.43 
 High Dose  
PMA (50ng/mL) 33.26 14.50 14.59 20.78±6.24 
RAVD (1000nM) 35.46 15.63 18.42 23.17±6.20 
Paired t-test p = 0.0475 
CD1d Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 23.71 *** 41.97 32.84±9.13 
RAVD (10nM) 45.26 35.73 47.34 42.78±3.57 
 Medium Dose  
PMA (10ng/mL) 39.88 26.95 39.96 35.60±4.32 
RAVD (100nM) 42.46 34.73 47.80 41.66±3.79 
 High Dose  
PMA (50ng/mL) 45.52 26.23 30.71 34.15±5.83 
RAVD (1000nM) 49.29 32.51 40.76 40.85±4.84 
Paired t-test p = 0.0059   
HLA-DR Low Dose Mean 
+/- SEM Exp1 
(Geo Mean) 
Exp2 
(Geo Mean) 
Exp3 
(Geo Mean) 
PMA (5ng/mL) 40.04 18.94 35.97 31.65±6.46 
RAVD (10nM) 39.43 31.52 41.43 37.46±3.03 
 Medium Dose  
PMA (10ng/mL) 37.37 23.90 38.71 33.33±4.73 
RAVD (100nM) 40.10 29.89 39.87 36.62±3.37 
 High Dose  
PMA (50ng/mL) 38.46 22.83 28.96 30.08±4.55 
RAVD (1000nM) 41.13 29.11 39.38 36.54±3.75 
Paired t-test p = 0.0066       ---   No data 
         ***Incalculable data 
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Table 1C.  Tabulated data of MFIs depicted in the flow cytometric analysis of receptors involved 
in antigen presentation on PMA or RAVD activated human THP-1 macrophages.   
THPs were activated with varying doses (as indicated) of PMA or a mix of RA and VD for 72 hrs and 
were stained for surface receptors using fluorescent antibodies and analyzed in a BD Facscan using 
Cellquest software. MFIs from triplicate experiments were tabulated and analyzed using a paired t-test 
to show significance at p<0.05 (*** indicates samples with no Geo Mean calculated during flow 
cytometry acquisition). 
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Figure 1D.  Flow cytometric analysis of DC-SIGN in human THP-1 macrophages activated with 
either RA alone, VD alone or their combination.  
THPs were treated with RA alone (1µM), VD alone (1µM) or thier combination (1µM each), stained for 
DC-SIGN using fluorescent antibodies and analyzed in a BD Facscan using Cellquest software at 24 hrs 
and 72 hrs after activation. Data show that RAVD combination induces the best expression of DC-SIGN 
in THPs (p values shown above bars for groups compared, t test; MFI±SD of 2 experiments). 
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Figure 2A.  Flow cytometric analysis of mannosylated-BSA-FITC (mBSA-FITC) in human THP-1 
macrophages activated with either PMA or RAVD before infection with H37Rv.  
THPs were activated for 3 days with either PMA or RAVD, treated with mBSA-FITC at 37oC and 
analyzed for uptake via macrophage-mannose receptor. RAVD enhanced the expression of macrophage-
mannose receptor compared to PMA activated or naïve cells (one of three similar experiments shown 
for histograms).    
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Figure 2B.  Flow cytometric analysis of mannosylated-BSA-FITC (mBSA-FITC) in human THP-1 
macrophages activated with either PMA or RAVD after infection with H37Rv.  
THPs were activated for 3 days with either PMA or RAVD, infected with H37Rv for 24 hrs, treated 
with mBSA-FITC at 37 °C and uptake was analyzed by flow cytometry. After infection, RAVD-THPs 
increased their uptake of mBSA-FITC compared to PMA activated cells (one of three similar 
experiments shown for histograms).    
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 (-) H37Rv (+) H37Rv 
PMA 
(Geo Mean) 
RAVD 
(Geo Mean) 
PMA 
(Geo Mean) 
RAVD 
(Geo Mean) 
Exp1 35.51 66.09 26.82 86.76 
Exp2 96.16 154.27 88.14 173.14 
Exp3 52.17 72.55 50.76 93.24 
 
Mean 
+/- SEM 
61.28±18.09 97.64±28.38 55.24±17.84 117.7±27.78 
Paired t-test p = 0.0009 between RAVD groups before and after infection 
 
 
Table 2.  Tabulated data of MFIs depicted in the flow cytometric analysis of mannosylated-BSA-
FITC (mBSA-FITC) uptake in PMA or RAVD activated human THP-1 macrophages.   
THPs were activated for 3 days with either PMA or RAVD, infected with or without Mtb H37Rv for 24 
hrs, then treated with mBSA-FITC at 37oC and uptake was analyzed by flow cytometry.  Tabulated data 
is graphically represented in Figure 2A and 2B. Paired t-test analysis between RAVD groups (-/+ 
H37Rv) shows an increase in mBSA-FITC uptake (p=0.0009). 
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Figure 3.  PMA and RAVD have differential effects on the uptake of Mycobacterium tuberculosis 
(Mtb) within THP-1 macrophages.  
THPs were activated with either 10 ng/mL of PMA or 1 μM each of RA and VD for 72 hrs and infected 
with Mtb H37Rv for 4 and 24 hrs.   Bacteria internalized in cultures of washed monolayers were 
visually scored by microscopy using acid fast stain.  Mtb uptake by THPs is significantly increased after 
RAVD treatment (* p < 0.009, t –test, mean±SEM of 3 experiments).  
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DISCUSSION 
 
Monocytes and monocytoid cell lines generally express reduced numbers of receptors and are 
less efficient in phagocytosing pathogens(86). However, differentiated macrophages express abundant 
receptors and are more phagocytic.  Monocyte to macrophage differentiation occurs after binding of 
pathogens to monocytes via their receptors in combination with the release of self-activating cytokines 
such as TNF-α, G-CSF and GM-CSF. Differentiation can be induced in vitro by phorbol esters(46), 
VD3(47) and RA(48). Although RA and VD have been shown to separately activate THPs, limited 
studies have looked into the synergistic effects of the two vitamins to induce a mature macrophage 
phenotype. 
 As Mtb is an intracellular parasite, it is phagocytosed by the macrophage where it can survive 
and multiply.  RAVD-THPs expressed higher levels of uptake and binding receptors (CD14, DC-SIGN, 
MMR) along with a corresponding increase in internalized Mtb during bacterial infection.  VD3 was 
found to enhance DC-SIGN levels in THPs earlier and the well documented role of DC-SIGN in 
mycobacterial recognition confirmed the increased efficacy of RAVD-THPs during phagocytosis. It is 
interesting to note that before and after infection, RAVD-THPs expressed higher levels of MMR than 
PMA-THPs.  Mtb phagocytosis facilitated by MMR has been suggested as an advantageous route of 
entry for the pathogen since internalization of this receptor is not directly linked to the activation of 
cytotoxic reactive oxygen intermediates(70).    Furthermore, uptake of mycobacterial glycolipids by 
MMR leads to decreased phagosome maturation rates in macrophages thus allowing greater bacterial 
survival(70).  It would be exciting if future studies could determine if binding of Mtb to specific 
receptors influences the response produced by the host cell.  These findings could help elucidate the 
mechanism by which Mtb is able to enter into a latent phase inside the host. 
 Following the uptake of Mtb into the phagosome, a step-wise process begins where phagosome-
lysosome fusion occurs.   This leads to the degradation of the pathogen and allows processed bacterial 
peptides to be loaded onto antigen presentation molecules for recognition by T-cells to induce a Th1 
immune response. Since RAVD-THPs, compared to PMA-THPs, expressed higher levels of HLA-DR, 
CD1d, CD80, CD86, we speculated that antigen presentation and cross-talk with T-cells would be better 
observed in these cells.  However, Mtb is also known to down-regulate antigen presentation receptors 
during infection(87).  Therefore, further evaluation of antigen presentation and cross-talk receptor 
expression during Mtb infection appeared to be necessary and are elaborated next.   
 Along with evaluating uptake and antigen presentation receptors, we were interested in the 
possiblity of using RAVD-THPs as a model for TB/HIV-1 co-infections.  Both CD195 and CD184, up-
regulated in RAVD-THPs, are important co-receptors in mediating HIV-1 entry into host cells(84).  DC-
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SIGN, another receptor shown to facilitate HIV-1 entry into immune cells, is also up-regulated in 
RAVD-THPs.  We speculated that RAVD-THPs may allow us to study Mtb/HIV-1 coinfections. 
 In conclusion, our studies show that RAVD transformed THPs to a more efficient macrophage 
phenotype than PMA. The observation that PMA-THPs were less able to phagocytose Mtb correlated 
well with their reduced expression of uptake receptors.  
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CHAPTER 3 
 
EFFECTS OF RETINOIC ACID AND VITAMIN D ON THE ABILITY OF THP-1 CELLS TO 
PRESENT ANTIGEN TO HUMANIZED MOUSE T-CELLS  
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INTRODUCTION 
 
Once we found Mtb internalized into THPs, we investigated the fate of ingested organisms.  
Usually the ingested Mtb are enclosed in a phagosome that fuses with lysosome in a process called 
maturation.  During maturation, Mtb is delivered to lysosomes for degradation and mycobacterial 
peptides are sorted to be eventually presented via MHC-II on the cell surface to T-cells. 
 
MHC-II Maturation 
 An important function of macrophages is their ability to present foreign antigens to T-cells, 
which release cytokines, such as IL-2, upon antigen recognition.  Unlike major histocompatibility 
complex class I (MHC-I) that presents peptides from cytosolic proteins, MHC class II (MHC-II) antigen 
presentation originates primarily from phagocytosed extracellular proteins or pathogens.  Therefore, as 
mentioned above, MHC-II antigen presentation is highly dependent on maturation of the phagosome 
into a phagolysosome.    
 Processing and loading of peptides to MHC-II molecules has been studied broadly although not 
as extensively in tuberculosis(88).  During synthesis in the endoplasmic reticulum (ER), MHC-II is a 
trimer composed of a dimer of α and β chain along with an invariant chain.  The invariant chain blocks 
the peptide-binding site while the MHC-II molecule is being processed in the ER to prevent cellular 
peptides from binding and being presented.  It also targets the MHC-II molecule for export via budding 
of the ER in a vesicle.  During acidification of the vesicle or endosome, the invariant chain is degraded 
but the peptide-binding site remains blocked by a residual peptide called Class II-associated invariant 
chain peptide (CLIP).  CLIP remains in place even when the MHC-II containing endosome merges with 
the matured phagosome containing endocytosed antigens.  Only when an MHC-II like structure, such as 
HLA-DR, binds to MHC-II does CLIP get released and peptides allowed binding.  Once peptides are 
bound, MHC-II can travel to the cell surface and present the antigen exclusively to CD4+ T-cells.  The 
latter have specific T-cell Receptors (TCR) that can bind MHC-II-peptide complex. 
 
MHC-II Molecules and Tuberculosis 
   Mtb has developed several strategies to inhibit macrophages without being detected and thus 
degraded.  One major mechanism is that it inhibits phagosome-lysosome fusion that enables it to avoid 
lysosome-mediated degradation.  This mechanism has been discussed in Chapter 6.  A second 
mechanism is to manipulate the antigen presentation pathway in MHC-II molecules.   The secreted 
bacterial lipoprotein, LpqH (also known as 19kDa) has been shown to down-regulate MHC-II surface 
expression by excessive signaling through Toll-Like Receptor 2 (TLR-2)(89-91). Extended exposure of 
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LpqH to TLR-2 receptor decreases the activity of MHC-II transcriptional activator (CIITA) that hinders 
gene expression of the MHC-II molecule(90, 91).  Paradoxically, TLR-2 signaling is more important 
during in vitro MHC-II presentation, since, chimeric animal studies have demonstrated that TLR-2 
deficient macrophages show no difference in the surface expression of MHC-II than wild-type(92).  
However, this observation can also be explained by the finding that LpqH-mediated down-regulation of 
MHC-II expression occurs exclusively in macrophages infected with Mtb(93).  Thus, even Bacillus 
Calmette-Guérin (BCG) vaccine, that also contains LpqH, when given to mice eventually causes 
decreased expression of MHC-II in vivo(93).   
 Additionally, Mtb can manipulate MHC-II intracellular trafficking to prevent antigen 
presentation from occurring. Since Mtb phagosomes already have MHC-II peptide, loading can occur in 
situ(94).  However, for MHC-II to be loaded properly with peptide, the compartment must be acidified 
to activate cathepsin proteases to cleave Mtb peptides along with the invariant chain of MHC-II.  Two 
important enzymes that are involved in MHC-II peptide loading are Cathepsin D (CatD), a protease that 
can cleave Mtb peptides(95) and Cathespin S (CatS), a lysosomal cysteine protease that is responsible 
for cleaving the invariant chain of MHC-II(96).   
To interfere with peptide presentation, Mtb has evolved several mechanisms to modulate the 
immune response.  First, Mtb decreases MHC-II expression by inducing IL-10, an anti-inflammatory 
cytokine, which leads to the inhibition of CatS function(97, 98).  Second, Mtb intra-phagosomally 
expresses a urease, encoded by the ureC gene, which catalyzes the hydrolysis of urea into carbon 
dioxide and ammonia(99).  The excess ammonia produced by the urease alkalizes the phagosomal 
compartment preventing it from acidifying thus inhibiting cathepsin activity critical for MHC-II peptide 
loading and maturation.   
Mtb has also been shown to exclude vacuolar proton-ATPase (v-ATPase) from the phagosomal 
compartments (100).  Bacterial v-ATPase phagosome exclusion prevents protons from being pumped 
into the compartment to keep it acidified.  In one study, v-ATPase phagosome exclusion was linked to 
the decrease in presentation of Antigen 85b(95), an important mycobacterial protein vaccine candidate 
eliciting T cell response to Mtb(101).   
 
MHC-II Antigen Presentation to Hybridoma CD4+ T-cell 
We previously determined that activation of THP cells with RAVD led to an increase in antigen 
presenting receptors, HLA-DR, CD1d, CD80 and CD86 (Figure 1C; Table 1C) compared to PMA-
THPs (Chapter 2).  Using two humanized mouse T-cell lines (kind gift of Dr. David Canaday)(91) that 
recognize peptides specific for Antigen 85B (F9A6 cells) and α-crystallin (5MB cells), we attempted to 
determine if the increase in surface expression of antigen presenting receptors led to an increase in T-
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cell priming resulting in Il-2 secretion.  Quantitation of IL-2 release by these T-cell hybridoma cell lines 
allowed us to evaluate the processing and presentation of mycobacterial antigens in activated THP 
macrophages.  A diagram of in vitro antigen presentation appears below. 
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Diagram 1:  Mtb antigen processing in macrophages and the detection of presented peptides on MHC-
II molecules by using F9A6 or 5MB humanized mouse cell lines specific for Antigen 85B and α-
crystallin, respectively. 
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RESULTS 
 
PMA and RAVD activated Mtb infected THP cells do not induce IL-2 secretion from T-cell 
hybridomas specific for Antigen 85B or α-crystallin 
We previously determined that activation of THP cells with RAVD led to an increase in antigen 
processing and presenting receptors, HLA-DR, CD1d, CD80 and CD86 (Figure 1C and Table 1C) 
compared to PMA-THPs.  Using F9A6 cells, which recognize Antigen 85b (Ag85b) and 5MB cells, 
which recognize α-crystalline (acr), we attempted to determine if mycobacterial antigen presentation 
was occurring in RAVD-THPs.  Unfortunately, our attempts to elicit an IL-2 T-cell response from 
activated and infected THPs were unsuccessful. In an experiment repeated several times, THPs were 
tested naïve or treated with IFN-γ, PMA or RAVD, followed by infection with Mtb H37Rv or BCG-14, 
a mutant strain of BCG vaccine that hyper-expresses Antigen 85B.  After infection, the cells were 
washed and overlaid with either F9A6 or 5MB T-cells.  The supernatants were collected and tested for 
IL-2 using sandwich ELISA.  
Earlier studies by Dr. Canaday’s laboratory demonstrated that Mtb infected THP cells activated 
with IFN-γ and overlaid with the hybridoma T-cells produced the most IL-2 secretion.  Following his 
suggested protocol, we attempted to determine the time course that would yield optimal IL-2 production 
(Figure 4A).  Unfortunately, after several attempts to find the most favorable infection time point, using 
either BCG-14 or Mtb H37Rv strains to infect IFN-γ activated THPs, we were unable to detect IL-2 
levels above control groups (no overlay with T-cells). 
Although IFN-γ activated THPs did not facilitate high levels of IL-2 secretion from F9A6 or 
5MB cells, we were curious to determine the effects of PMA and RAVD (Figure 4B).  BCG-14 was 
used to infect PMA-THPs and RAVD-THPs at various infection times (4 hrs and 24 hrs), the cells 
washed, then overlaid with F9A6 for 4 hrs or 24 hrs.  The supernatants were collected and tested for IL-
2 using sandwich ELISA. Again, the levels of IL-2 detected did not rise above the controls groups (no 
overlay with T-cells). 
 Since we did not detect any increase in supernatant IL-2 levels using varying conditions of 
activated and infected THPs, we decided to evaluate the effects of another cell line, MonoMac-6, an 
antigen presenting macrophage (Figure 4C).  THP-1 and MonoMac-6 cells were treated with either 
IFN-γ or RAVD and infected with either BCG-14 or Mtb H37Rv for 4 hrs.   The infected macrophages 
were washed and overlaid with F9A6 cells for an additional 4 hrs.  The supernatants were collected and 
evaluated for IL-2 using sandwich ELISA.  Unfortunately, the change of macrophage cell lines also did 
not lead to an increase in IL-2 levels above background (normally considered over 250 pg/mL). 
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Figure 4A.  Evaluation of MHC-II dependent antigen 85B (Ag85B) presentation in BCG-14 or M. 
tuberculosis H37Rv infected THP-1 macrophages activated with IFN-γ using humanized mouse T-
cells secreting IL-2.  
 Macrophages were activated with IFN-γ and infected with either BCG-14 (mutant BCG strain hyper-
expressing Ag85B) or H37Rv.  After infection, the cells were washed and overlaid for 4 hrs. with either 
F9A6, a T-cell specific for Ag85B, or 5MB,  a T-cell specific for α-crystalline (acr). Supernatants were 
collected and tested for IL-2 using sandwich ELISA.  Supernatants collected from overlaying with 
either F9A6 or 5MB did not show IL-2 levels above control groups (no overlay with T-cells). 
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Figure 4B. Evaluation of MHC-II dependent Ag85B presentation in PMA or RAVD activated 
THP-1 macrophages using F9A6 cells specific for Ag85b.   
Macrophages were activated with PMA or RAVD and infected with BCG-14 (mutant BCG strain hyper-
expressing Ag85B).  After infection, the cells were washed and overlaid for either 4 hrs or 24 hrs with 
F9A6, a humanized mouse T-cell specific for Ag85B. Supernatants were collected and tested for IL-2 
using sandwich ELISA.  Supernatants collected from overlaying with F9A6 did not show IL-2 levels 
above control groups (no overlay with T-cells). 
  
36 
 
 
 
 
 
 
-10
0
10
20
30
F9A6 Overlay
No F9A6 Overlay
IFN-γ RAVD IFN-γ RAVD IFN-γ RAVD IFN-γ RAVD
MonoMac-6 MonoMac-6THP-1 THP-1
H37Rv BCG-14 (Antigen 85B)
IL
-2
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
 
 
Figure 4C.  Comparison of MHC-II dependent Ag85B presentation in THP-1 or MonoMac-6 
activated macrophages using F9A6 cells.   
Macrophages were activated with IFN-γ or RAVD and infected with BCG-14 (mutant BCG strain 
hyper-expressing Ag85B) or M. tuberculosis H37Rv. After 4 hr infection, the cells were washed and 
overlaid for 4 hrs with F9A6, a T-cell specific for Ag85B. Supernatants were collected and tested for 
IL-2 using sandwich ELISA.  Supernatants collected from overlaying with F9A6 did not show IL-2 
levels above control groups (no overlay with T-cells). 
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DISCUSSION 
 
 IL-2 production by antigen specific hybridoma T-cells is a well established technique used to 
demonstrate MHC-II presentation by antigen presenting cells (APCs)(102).  We examined the ability of 
two humanized T-cell hybridoma cell lines, F9A6 and 5MB, to detect antigen presentation in RAVD 
and PMA activated THPs infected with mycobacteria.  Although the hybridoma cell lines grew in 
culture and remained viable during co-culture with infected macrophages, IL-2 release could not be 
detected above the baseline level.   
 Initial consultation with Dr. Canaday, the donator of the F9A6 and 5MB cell lines, led us to 
initiate our antigen presentation studies using IFN-γ activated THPs. Since previous studies determined 
that there is a difference in antigen presentation between macrophages infected with virulent and 
avirulent mycobacteria strains(89, 103), we infected our THPs with either Mtb H37Rv (virulent) or 
BCG-14 (avirulent vaccine candidate).  Phagosomes containing either H37Rv or BCG-14 have been 
shown to process and present Ag85b, a mycobacterial protein important in human T cell response to 
Mtb(101).  Given assurances by Dr. Canaday that IFN-γ activated THPs would be the best presenters of 
antigen to the hybridoma cell lines, we were disappointed to discover that no IL-2 production was 
detected in our ELISA assays (Figure 4A).  Variations in the IFN-γ dose, MOI infection rates and 
macrophage:T-cell ratio during overlay, all yielded similar negative results (data not shown). 
 Published work demonstrating that F9A6 could recognize antigen presentation by PMA-
THPs(91) led us to our next endeavor (Figure 4B).  We opted to focus strictly on F9A6 since Dr. 
Canaday communicated it was a more reliable cell line than 5MB, which on occasion gave inconsistent 
results.  Since F9A6 recognizes peptides processed from Ag85b, we infected our macrophage with 
BCG-14, a mutant BCG strain that super-secrets Ag85B, with the hope of increasing antigen 
presentation.  Our previous work in antigen presentation using mouse macrophages overlaid with mouse 
T-cell hybridomas demonstrated that the optimal incubation time for macrophage:T-cell co-culture was 
4 hrs.  This differed from the published work(91) that used an incubation overlay time of 24 hrs.  
Therefore, we opted to vary the overlay and infection times to increase the chance of positive results.  
Regrettably, IL-2 levels detection did not exceed baseline (250 pg/mL).  Several repeated experiments 
were conducted using varying doses of BCG-14 resulting in similar negative results (data not shown).   
           Our final attempt at determining antigen recognition by our T-cells was to use another monocytic 
cell line, MonoMac-6 (kindly donated by Dr. Andrew Rice, Baylor Collge of Medicine, Houston, 
Texas).  Similar to THP-1 cells, MonoMac-6 is a monocytic cell line that upon activation with IFN-γ, 
exhibits a mature macrophage phenotype(104). Once more, we were unable to detect IL-2 levels above 
background.  Several experiments were attempted using MonoMac-6 and various conditions, all of 
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which presented negative results (data not shown).  Also, a single experiment using human peripheral 
blood monocytic cells (PBMCs) donated by Dr. Rice was conducted with similar negative results (data 
not shown).   
 Since we were unable to confirm the correlation between the increase in antigen presentation 
molecules (HLA-DR, CD1d, CD80 and CD86) in RAVD-THPs with an increase in T-cell recognition 
and IL-2 secretion, we tentatively propose that either Mtb resides in an inactive state in THPs or 
interferes with antigen presentation by unknown mechanisms.  Additional studies are needed in this 
direction. 
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CHAPTER 4 
 
RAVD INDUCES OXIDANTS, AUTOPHAGIC PATHWAYS AND  
CATHELICIDIN TO DECREASE VIABILITY OF  
INTRACELLULAR MYCOBACTERIUM TUBERCULOSIS 
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INTRODUCTION 
 
Macrophage Mycobactericidal Mechanisms  
 Although, Mtb infects approximately one-third of the human population each year only a about 
10% of those infected develop active tuberculosis(1).  In most infected individuals, a healthy immune 
response eliminates the pathogen or keeps it “walled off” in a latent state where no disease manifests(1).  
Therefore, it appears that macrophages, the primary target of Mtb infection, have developed several 
mechanisms to control or eliminate the bacteria.  Since RAVD are routinely ingested by humans, we 
hypothesized that they could potentially trigger four mechanisms that could control Mtb infection. 
 
Reactive Oxygen Species (ROS) 
 A powerful macrophage defense mechanism to combat bacterial infections is to induce a 
process called “oxidative burst” or “respiratory burst”(105).  This process produces large quantities of 
reactive oxygen species (ROS) by activating phagocyte oxidase (phox), also known as nicotinamide 
adenine dinucleotide phosphate-oxidase (NADPH-oxidase).  Phagocyte oxidase is composed of six 
protein subunits that assemble on phagosomes during macrophage activation.  The activated phagocyte 
oxidase complex, which contains the p47phox and p67phox subunits, catalyzes the transfer of electrons 
from cytosolic NADPH to superoxide anions inside the phagosome(105).   
 The importance of ROS in controlling bacterial infections can be seen in patients with chronic 
granulomatous disease (CGD), a congenital disorder where a mutation occurs in any of the four phox 
subunit proteins, resulting in a failure to produce a proper ROS response(106).  Thus, patients with 
CGD have a higher susceptibility to pyogenic infections, such as Staphylococcus aureas, Aspergillus 
species, and Nocardia species(106).  CGD is also implicated in higher susceptibility to TB infection, 
where some estimates calculate CGD patients to be 170 times more likely to contract the disease than 
the general immunocompetent population(107, 108).  
 
Reactive Nitrogen Species (RNS) 
 A potent antimycobacterial mechanism, in macrophages, is the induction of a family of 
isoenzymes called nitric oxide synthases (NOSs).   During infection, IFN-γ signaling recruits inducible 
NOS (iNOS) to Mtb-containing phagosomes.  iNOS oxidizes guanidino nitrogen of L-arginine to 
produce nitric oxide (NO) and citrulline.  Then, NO rapidly reacts with molecular oxygen and water to 
eventually generate reactive nitrogen species (RNS)(109). In addition, highly reactive peroxynitrite 
(ONOO−) is formed by the combination of NO and superoxide produced by phagocyte oxidase leading 
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to bacterial death(110).  NO itself is a very potent antimycobacterial agent that kills 99% of cultured 
Mtb at low concentrations of <100 ppm (111). 
 The role of RNS in human tuberculosis is controversial.  In murine TB studies, iNOS activation 
and NO production has been shown to be a major pathway in controlling the disease(112).  However, in 
early human TB studies, RNS was difficult to detect leading most researchers to discount its importance 
in disease control(109). Initial human studies of RNS relied on the use of Greiss reagent, a chemical 
used to determine the presence of nitrites in samples.  This posed a problem since NO production leads 
to both nitrate (NO3-) and nitrite (NO2-) metabolites with levels below the sensitivity range of Griess 
reagent(113).  Current studies that utilize more sensitive probes, such as diaminonaphthalene (DAN), 
and NOS inhibitors, such as L-NG-monomethylarginine (L-NMMA), have demonstrated the ability of 
human macrophages to produce NO in response to Mtb infections (112, 114). 
 
Autophagy 
 A newly discovered pathway to control TB invasion of the host cell is through autophagy(36).  
Autophagy was initially discovered as a pathway for the cell to catabolize damaged cytosolic 
components as well as a means to produce metabolites and energy under starvation conditions(115). In 
TB infections, autophagy functions to enhance host resistance by circumventing MTB-induced 
phagosome maturation arrest(36, 116).  During autophagy, immature phagosomes containing Mtb, are 
tagged with a succession of autophagy related genes (Atg) proteins, starting with Atg6 (Beclin-1).  The 
attachment of beclin-1 to the membrane initiates the recruitment of other Atg proteins that complex onto 
the phagosome to form the distinctive double membrane feature of autophagy, the autophagosome.  
Ultimately, the autophagosome complex of proteins initiates the cleavage of cytosolic microtubule-
associated protein 1 light chain 3 (LC3-I; also known as Atg8) into its active form LC3-II.  LC3-II 
integrates into the autophagosomal membrane allowing fusion with lysosomes to form the 
antimycobacterial autophagolysosome(115).   
 Interestingly, Vitamin D has been shown to play a role in autophagic processes.  A recent study 
of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and an analog, EB1089, has revealed the induction of 
autophagy to promote cell death in human breast adenocarcinoma cell line(117).  Another significant 
study demonstrated that binding of TLR-1/2 and its co-receptor, CD14, to Mtb lipoprotein LpqH, 
activated Vitamin D-dependent antimycobacterial mechanisms to initiate autophagic processes and 
cathelicidin recruitment to the MTB-phagosomes(118).   
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Diagram 2:  Vitamin A and D induce two anti-mycobacterial pathways, cathelicidin and autophagy to 
control intracellular Mycobacterium tuberculosis growth. 
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Cathelicidin 
 Although there are a number of studies into the antimicrobial mechanisms controlling TB 
infection, there is scant information on anti-microbial peptides.  One such important peptide, 
cathelicidin (hCAP-18/LL-37), has been shown to be regulated by either Toll-like receptor (TLR-
1/2(19), TLR-4(119) and TLR-9(119)) activation, 1,25(OH)2D3(120)  (a metabolite of Vitamin D3) or 
retinoic acid(121, 122), and contribute to the control of tuberculosis.  Cathelicidin is a family of 
lysosomal peptides that have direct mycobactericidal properties and cause lysis upon direct contact with 
bacterial surfaces(119).  In addition, cathelicidin has recently been shown to be an important immuno-
regulator of autophagy.  siRNA knock-down studies of cathelicidin demonstrated that it was required to 
induce autophagy in 1,25(OH)2D3  treated cells by activating transcription of the autophagy-related 
genes Beclin-1 and Atg5(123).    
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RESULTS 
 
PMA and RAVD have differential effects on the survival of Mycobacterium tuberculosis (Mtb) in 
THPs   
One of the most important functions of mature and fully activated macrophages is to control and 
eliminate bacterial infections.  Activated THPs were infected with Mtb H37Rv (MOI of 10) and 
evaluated for control of intracellular bacterial growth.  Subsequent to increased uptake (Figure 3), 
RAVD-THPs controlled the infection with Mtb better than PMA-THPs (Figure 5).  Mtb grew 10-fold in 
10 days within PMA-THP macrophages while RAVD decreased Mtb numbers by one log10 in 10 days 
of infection. Thus, RAVD exerted anti-tuberculosis effects. 
 
RAVD induce enhanced levels of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) response in THPs that leads to the inhibition of intracellular Mtb.   
In order to determine the basis for the anti-tuberculosis effects of RAVD, ROS and iNOS 
production was evaluated during Mtb infection of THPs.  When Mtb is internalized by macrophages, it 
is sequestered within a phagosome that triggers the acquisition of the multimeric components of the 
NADPH oxidase (phagocyte oxidase; phox). In our earlier study(124), we demonstrated that NADPH 
oxidase colocalizes with Mtb phagosomes in macrophages. The colocalization, evidence of targeting of 
the ROS complex to Mtb phagosomes, is detectable using antibody stain against p47/67phox components 
(124). Accordingly, RAVD or PMA treated THPs were infected with Mtb gfpH37Rv and 
immunostained and scored microscopically for colocalization (124). PMA-THPs showed a reduced 
colocalization of the NADPH oxidase proteins with Mtb phagosomes while RAVD-THPs showed an 
enhanced colocalization (Figure 6A-B).  
These microscopic studies correlated with intracellular levels of ROS in PMA and RAVD 
activated THPs, which was determined using a ROS specific probe, 2’,7’-dichlorodihydrofluorescein 
diacetate (H2DCFDA).  Non-fluorescent H2DCFDA is cleaved by intracellular esterases to yield the 
dichlorofluorescein (DCF) that is then oxidized by ROS to yield a fluorescent hydrophobic product 
trapped within the cell. Figure 6C shows the flow cytometric analysis of fluorescent ROS positive cells 
after activation and before infection as analyzed by flow cytometry. PMA-THPs showed an increased 
shift due to ROS induced fluorescence on day 1 that returned to background levels by day 3. On the 
other hand, RAVD-THPs showed a shift on day 1 that was sustained until day 3 when the cells were 
infected with Mtb. The specificity of ROS mediated conversion of DCF was confirmed by using the 
ROS inhibitor, diphenyleneiodonium (DPI) (data not shown). Intracellular ROS was also quantitated 
following activation and Mtb infection using an Ascent-Fluoroscan fluorometer, as Mtb infected THPs 
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could not be loaded to the flow cytometer for safety reasons. RAVD-THPs with internalized Mtb 
showed increasing ROS levels over 5 days while PMA-THPs showed a spike that declined by day 5 
(Figure 6D). Together, these studies indicate that both before and after infection, RAVD-THPs had 
stronger ROS response than PMA-THPs.  
Finally, ROS specific effects were correlated to bactericidal killing. THPs were activated in the 
presence or absence of 10 mM each of diphenyleneiodonium chloride (DPI), an inhibitor of ROS 
response or 10 μM N-methyl-monoarginine (NMMA), an inhibitor of nitric oxide response. After 
inhibition, cell lysates of infected RAVD-THPs were plated for viable colony counts (CFU) at the end 
of 24 and 72 hrs infection. At both time points, inhibition of ROS response with DPI increased viability 
of intracellular Mtb compared to inhibition of NO response (Figure 6E).  
 
RAVD induced autophagy in THPs leads to inhibition of Mtb growth.   
A recent study demonstrated that Vitamin D3 can induce autophagosome formation to kill 
internalized Mtb(123).  Since autophagy could be another antimicrobial pathway that can control Mtb 
infection, we investigated the ability of RAVD to induce autophagy.  We addressed this issue in three 
experiments. 
First, RAVD or PMA activated THPs were infected with Mtb H37Rv and their phagosomes 
were purified using a sucrose gradient.  Western blot analysis demonstrated that Mtb phagosomes from 
RAVD-THPs recruited more beclin-1, an initiator molecule of autophagy, than those from PMA-THPs 
(Figure 7A).   
Second, we blocked autophagy in THPs to determine effects of siRNA knock-down of beclin-1 
expression.  RAVD-THPs were treated or untreated with siRNA vs. beclin-1, to abolish autophagy and 
then were infected with Mtb. Figure 7B shows that knock-down of autophagy led to an increase in 
intracellular survival of Mtb and thus RAVD induced killing of Mtb was inhibited by siRNA vs. beclin-
1. Furthermore, when Mtb phagosomes of such macrophages were stained using an autophagosome 
marker, phagosomes colocalized with monodansylcadaverine (MDC) in RAVD-THPs while MDC 
uptake was absent in siRNA knockdown THPs (Figure 7C). Indeed, the THPs here needed to be stained 
with a nuclear DAPI stain to visualize macrophages. These data suggested that the bactericidal activity 
of RAVD was also attributable in part to the induction of autophagy.   
Finally, we performed an additional analysis of purified phagosomes using Western blot for a 
panel of autophagic molecules and this panel showed differential recruitment of proteins to Mtb-
containing phagosomes (Figure 7D).  Mtb phagosomes of RAVD-THPs recruited increased amounts of 
autophagy proteins (Atg16L, Atg4b, Atg7, Beclin-1 and LC3) to its phagosomes in comparison to those 
from PMA-THPs.  Positive control groups where serum starvation (SS) was used to induce autophagy 
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showed similar or lower levels of proteins in comparison with RAVD-THPs.  The addition of 3-
methyladenine (3-MA) to THP cultures was intended to inhibit autophagy but showed higher levels of 
proteins after treatment than before (naïve). It is however known that 3-MA besides inhibiting 
autophagy also has other non-specific effects on endosome traffic.  
 
RAVD increases levels of cathelicidin in THPs infected with Mtb.   
 Cathelicidin is a potent bactericidal peptide that has been shown to be important in controlling 
Mtb infection.  We were interested to know if the combined effects of RAVD could induce cathelicidin 
expression.  Western blot analysis of Mtb H37Rv infected PMA-THPs and RAVD-THPs demonstrate 
that high levels of cathelicidin is expressed in the latter versus former cells (Figure 8).  
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Figure 5.   PMA and RAVD have differential effects on the survival of Mycobacterium tuberculosis 
(Mtb) within THP-1 macrophages.  
THPs were activated with either 10 ng/mL of PMA or 1 μM each of RA and VD for 72 hrs and infected 
with Mtb for 24 hrs.  The cells were washed three times to remove non-phagocytosed bacteria, 
incubated for 10 days with media, aspirated, pelleted, and lysed in 0.05% SDS within the same well thus 
accounting for adherent as well as some floating macrophages, and plated for colony (CFU) counts. 
RAVD treatment inhibited bacterial replication while Mtb showed an increase in colony counts in PMA 
treated macrophages (* p < 0.009, t test, mean±SD of 3 experiments).  
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Figure 6A.  Enhanced co-localization of gfpH37Rv with components of the phagocyte (NADPH) 
oxidase in RAVD activated THP-1 macrophages.   
THPs were activated with either PMA or RAVD and phagocytosed with gfp-expressing strain of Mtb 
(gfpH37Rv) for 4 hrs followed by fixation and staining with primary Texas Red fluorescent antibodies 
against p47/p67phox components of the phagocyte (NADPH) oxidase followed by Texas-Red conjugate.  
Arrow in bottom panels shows a co-localizing gfpH37Rv, while the arrowhead shows a non-
colocalizing gfpH37Rv.    
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Figure 6B.   Analysis of co-localization of gfpH37Rv with components of the phagocyte (NADPH) 
oxidase in PMA or RAVD activated THP-1 macrophages.   
Percentage of positive gfpH37Rv phagosomes were scored for colocalization with p47/p67phox in 
activated and infected THPs.  RAVD-THPs recruited more phox proteins to the Mtb-containing 
phagosomes than PMA-THPs.  Bacteria of over 100 macrophages in each chamber of triplicate well 
slides were counted and averaged from three separate experiments. (p values shown above bars for 
groups compared, t test; mean±SD of 3 experiments). 
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Figure 6C.  RAVD induce enhanced reactive oxygen species (ROS) response in THP-1 
macrophages before infection with M. tuberculosis H37Rv.  
THPs activated with PMA or RAVD were labeled with 2’,7’-dichlorodihydrofluorescein diacetate 
(H2DCFDA), a probe for intracellular ROS and quantitated using flow cytometry on day 1 (black), day 
2 (green) and  day 3 (blue).  RAVD-THPs maintained ROS production over 3 days, whereas ROS 
response declined in PMA-THPs after day 2 (one of three similar experiments shown).  Red fill shows 
basal levels of ROS production in naïve (unactivated) THPs.  
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Figure 6D.  RAVD continue to induce enhanced reactive oxygen species (ROS) response in THP-1 
macrophages after infection with H37Rv.  
THPs activated with PMA or RAVD were labeled with H2DCFDA, a probe for intracellular ROS, and 
using an Ascent-Fluoroscan, ROS production was quantitated and expressed as in average fluorescence 
units (AFU). Data show that ROS increased in RAVD-THPs over three days of activation but decreased 
by day 3 in PMA-THPs (t test; mean±SEM of 3 experiments). 
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Figure 6E.  Inihibition of ROS and RNS leads to increased intracellular survival of M. tuberculosis 
in RAVD-THPs.  
ROS and RNS inhibitors (left panel):  THPs were activated with RAVD, infected with Mtb and then 
incubated in the presence or absence of 10 mM of diphenyleneiodonium chloride (DPI), an inhibitor of 
ROS response, or 10 μM of N -monomethyl-L-arginine (L-NMMA), an inhibitor of nitric oxide 
response.  Macrophage lysates were then plated for CFU counts at the end of 24 and 72 hrs of infection. 
Inhibition of ROS response with DPI increased the viability of intracellular Mtb compared with 
inhibition of NO response (p values shown above bars for groups compared, t test; 3 experiments).  ROS 
and RNS levels after inhibition (right panel): Supernatants of macrophage cultures of macrophage 
cultures were tested with H2DCFDA or diaminonapthalene (DAN) respectively for ROS or NO induced 
average fluorescence units (AFU) using an Ascent fluoroscan. 
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Figure 7A.  M. tuberculosis phagosomes purified from RAVD-THPs show greater amounts of 
beclin-1 during Western blot analysis.   
PMA and RAVD activated THPs were infected for 4 hrs with Mtb H37Rv (MOI of 10) and the 
phagosomes purified using sucrose gradients. Isolated phagosomes were analyzed by Western blot using 
antibodies specific to beclin-1.  Phagosomes of RAVD-THPs have an increased level of beclin-1 than 
those from PMA-THPs. One of three independent experiments with similar results is shown. 
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Figure 7B.  RAVD induces autophagy in THP-1 macrophages that leads to inhibition of 
intracellular M. tuberculosis.   
RAVD activated THPs were treated or untreated with siRNA vs. beclin-1, to abolish autophagy, and 
were infected with Mtb (MOI of 10). Lysates were then plated for CFU counts at the end of 24 hrs 
infection. Inhibition of autophagy with siRNA beclin-1 increased the viability of intracellular Mtb 
compared to siRNA Control (p values shown above bars for groups compared, t test; ±SEM of 3 
experiments). 
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Figure 7C.  siRNA inhibition of beclin-1 leads to reduced autophagosome formation in 
gfpMtb infected RAVD-THPs. 
RAVD activated THPs were treated or untreated with siRNA vs. beclin-1 to abolish autophagy, and 
were infected with Mtb gfpH37Rv (MOI of 10).  Monodansyl cadaverine (MDC) was used to label 
autophagosomes in infected RAVD-THPs. gfpH37Rv colocalizes with MDC in RAVD treated 
macrophages. MDC uptake was poor in siRNA vs.beclin-1 macrophages so that the nuclei were labeled 
with DAPI to visualize macrophages and gfpH37Rv. 
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Figure 7D.  M. tuberculosis phagosomes of RAVD-THPs recruit more autophagy proteins during 
Western Blot analysis.   
THPs were left untreated (naïve), activated with PMA or RAVD, serum starved (SS) to induce 
autophagy or treated with 3-methyladenine (3-MA) to inhibit autophagy.  Macrophages were infected 
for 4 hrs with Mtb H37Rv (MOI of 10) and the phagosomes purified using sucrose gradients. Isolated 
phagosomes were analyzed by Western blot using antibodies specific to various autophagy related 
proteins. RAVD-THP derived phagosomes had an increased presence of autophagic proteins than those 
from PMA-THPs. One of three independent experiments with similar results is shown above. 
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Figure 8.   RAVD induces cathelicidin expression in THPs infected with M. tuberculosis H37Rv.   
PMA and RAVD activated THPs were infected for 4 hrs with Mtb H37Rv (MOI of 10) and the cells 
cultured for 24 hrs. Whole cell lysates were analyzed by Western blot using antibodies specific to 
cathelicidin. RAVD-THP lysates showed an increased presence of cathelicidin than PMA-THPs. One of 
three independent experiments with similar results is shown above. 
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DISCUSSION 
 
 Monocyte to macrophage maturation leads to increased receptor expression, phagocytosis and 
enhanced mechanisms of bactericidal activity.  We have previously demonstrated that RAVD-THPs had 
increased receptor expression and phagocytic ability than PMA-THPs.  In this study, we show that even 
though RAVD-THPs are more phagocytic and carry a heavier internal Mtb burden (Figure 3), they are 
better able to control bacterial growth than PMA-THPs (Figure 5). This observation led us to 
investigate the antimicrobial activities that RAVD could generate in terms of the induction of reactive 
oxygen species (ROS), reactive nitrogen species (RNS), cathelicidin and autophagy.   
Our initial studies indicated that inhibition of iNOS with NMMA enhanced the survival of 
intracellular Mtb in RAVD-THPs although, curiously, we did not find significant levels of nitrate, an 
indicator of NO synthesis in the medium. It is possible that NO is induced but at such low levels that are 
not detectable by the Greiss reagent. RA(125) and VD3(126) has been reported to induce iNOS in murine 
and human macrophages and it remains to be determined whether their combination induces sustained 
iNOS in THPs. Given that inhibition of iNOS led to increased bacterial survival only after 72 hrs, it is 
tempting to speculate that RNS response may be time dependent and could contribute more in long term 
control of bacterial infection than acute disease. 
 The bactericidal function of RAVD-THPs was partly due to the induction of ROS since the 
ROS inhibitor, DPI, significantly enhanced Mtb survival (Figure 6E).  In a recent study, phagocyte 
(NADPH) oxidase was shown to be critical for 1,25(OH)2D3-mediated mycobactericidal response by 
activating cathelicidin expression via TLR-2 signaling of ROS responses(127).  Our model confirms this 
finding along with several other separate studies that demonstrate RA and VD separately induce ROS 
response(122, 128) and cathelicidin(121, 122).  However, unlike previous studies, our model 
demonstrates a strong induction of ROS even without internalized pathogen, where TLR signaling does 
not occur.  It would be interesting to determine if the combination of RA and VD led to a synergistic 
interaction greater than if the vitamins are given separately.   
 Recently, a study showed that Vitamin D3 alone can induce autophagosome formation to kill 
internalized Mtb(123).  Knock-down of beclin-1, a key protein involved in targeting vesicles for 
autophagy, demonstrated that RAVD can also activate autophagy to keep intracellular Mtb growth in 
check.  PMA-THPs consistently showed little to no beclin-1 present on their Mtb-containing 
phagosomes.  However, after 24hrs of Mtb infection, Atg5 was found on PMA-THPs while not being 
present on RAVD-THPs.  This result is interesting since it suggests that RAVD-THPs may be 
undergoing an alternative autophagy pathway that is Atg5-independent(129) or that PMA-THPs are 
inducing autophagy but at a much slower rate than RAVD-THPs.  Since the role of cathelicidin in 
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inducing alternative autophagy is still unstudied, our model may be a good method to investigating this 
pathway.  That RAVD induces four major antimycobacterial mechanisms suggests that they act as basic 
regulators of innate host defense. 
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CHAPTER 5 
 
MYCOBACTERIUM TUBERCULOSIS INFECTION FOLLOWED BY LONG TERM 
ACTIVATION WITH RAVD LEADS TO MULTINUCLEATED GIANT CELL (MNGC)  
FORMATION IN THP-1 MACROPHAGES 
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INTRODUCTION 
 
Granulomas and Tuberculosis 
A signature feature of tuberculosis is the granuloma formation histologically evident in the 
infected lungs and other organs.  The major function of granulomas in tuberculosis is the containment of 
Mtb to a localized area that prevents the spread of disease to other healthy regions of tissue.  The 
structure, function and evolution of granulomas have been studied using various animal models(130-
132), within lungs of tuberculous humans(133-135), explant(3, 136-138) and cell cultures in vitro(139). 
These studies have identified that monocytes infected with Mtb differentiate into macrophages, 
epithelioid cells and several types of multinucleate giant cells (MNGCs).  Many of these studies 
emphasize the critical role of MNGCs in bacterial containment and clearance within the granuloma.  
 
Multi-nucleated Giant Cells and Tuberculosis 
 Although the presence of MNGCs was described early in TB research(3), their precise 
formation and their contribution in TB pathogenesis is only recently being elucidated.  Cultured 
monocytes and macrophages have been induced to differentiate into MNGCs by exposure to various 
stimulants, such as cytokines(71, 140-143), lectins(144, 145), monoclonal antibodies(146-148) and 
conditioned media(149-152).  However, Mtb is a slow growing organism with a doubling time of about 
18 hours and the interaction of Mtb and macrophages is a chronic process in vivo, while, the available 
models are limited by their short lived macrophages.  
In this study, we discovered that human THP-1 cells treated with physiologically compatible 
vitamins like RA and VD and infected with live Mtb induce a differentiation process that result in the 
generation of MNGCs. We have studied these MNGCs for their phenotypic properties and to determine 
their possible functionality during tuberculosis. 
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RESULTS 
 
Activation of THP-1 macrophages with RAVD leads macrophage to differentiate into giant cells  
A striking change observed during in vivo tuberculosis is the morphological transformation of 
macrophages that yield various morphotypes in guinea pigs, rats, rabbits and humans (153-155). They 
include giant cells, spindle cells, fibroblast like cells and epitheliod cells. This suggested that 
macrophage activation may lead to differentiation and giant cells.  However, we noted that, PMA-THPs 
with phagocytosed Mtb progressively led to a loss of viability of macrophages after seven days due to 
uncontrolled growth of mycobacteria (Figure 9A).  On the other hand, RAVD-THPs were able to 
control Mtb infection and prevent loss of viability in macrophages. In our studies, viability was 
constantly monitored using Alamar blue vital dye. Furthermore, RAVD induced cell fusion to form 
giant cells. Figure 9B illustrates the growth curve of intracellular Mtb recovered from RAVD treated, 
adherent macrophages between days 1-10 and then from adherent multinucleate giant cells (MNGCs) 
between days 10-35. Figure 9C illustrates the nuclear morphology of DAPI stained MNGCs that 
contain gfpH37Rv observed over a period of 30 days in vitro culture. Finally, when MNGCs fuse with 
additional macrophages, the zone of fusion is delineated by characteristic ‘inter-digitating septae’ 
observable only through electron-microscopy (EM). For example, Figure 9D illustrates an EM image of 
MNGC fusing with individual THP.   
We also sought to determine the mechanism of cell fusion. It has been reported that ‘a 
disintegrin and metalloproteinase’ (ADAM) family of proteins mediate cell fusion that occurs during 
osteoclast formation as when mycobacteria induce cell fusion (156). We therefore stained RAVD-THPs 
for several ADAMs and found that RAVD induced only a transient staining for ADAM-9 between 
THPs undergoing cell fusion early after infection (Figure 10).  
 
Long-term activation of THP-1 macrophages with RAVD leads to long living MNGCs that 
contain persistent M. tuberculosis  
Since RAVD-THPs remained viable even after several weeks and such macrophages contained 
gfpH37Rv, although in low numbers (Figure 9C), we sought to determine if long term activation with 
RAVD led to a long-living ‘macrophage reservoir’ that contained persistent Mtb. Since PMA-THPs die 
by 7-10 days in Mtb infection and other in vitro macrophage models do not permit long term cultures of 
Mtb, it appears that there are no in vitro cell culture models to study long term persistence of Mtb.  Most 
reports of macrophages in culture show loss of viable cultures by day 28 or less. We therefore optimized 
a protocol of activation of THPs that included repeated pulsing of RAVD to MNGCs through a supply 
of freshly activated THPs to expand adherent Mtb infected MNGCs in vitro. We hypothesized that 
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adherent, pre-formed MNGCs would fuse with incoming, freshly activated THPs leading to larger 
MNGCs, which contained non-replicating Mtb and survived longer. Figure 11A shows adherent, well 
differentiated MNGC that have gfpH37Rv and overlaid with single THPs that are strongly stained with 
carboxyfluorescein diacetate (CFSE). The MNGCs were found to fuse with freshly added THPs.  Such 
fused MNGCs with intact gfpH37Rv could be maintained in culture for as long as 60 days (phase 
contrast image of day 60 MNGC, Figure 11A).  Our cultures remain the longest period for which Mtb 
infected macrophages have been maintained viable in culture to date (Table 2). 
In order for MNGCs to survive and differentiate, an optimal growth environment is necessary 
where cytokine signalling may be required, both for self-activation and to recruit mononuclear cells in 
vivo.  Furthermore, it is well established that cytokine treatment of human peripheral blood derived 
monocytes or rat macrophages can lead to the formation of short lived MNGCs(157, 158). To determine 
whether cytokines could regulate the survival of MNGCs in culture, THPs were activated with either IL-
4 or GM-CSF or their combination followed by infection with Mtb. The key issue we wished to 
determine was whether cytokines such as IL-4 and GM-CSF were enough to create MNGCs or was 
RAVD required for long living MNGCs.  Figure 11A (bar graph) illustrates the survival of MNGCs 
after cytokine alone or RAVD activation. IL-4 and GM-CSF tested alone or in combination did result in 
MNGCs, although they did not prevent the growth of Mtb and as a consequence, Mtb ultimately 
destroyed the MNGCs between days 12-14. Thus, only RAVD treatment was found to induce long 
lasting MNGCs and addition of either IL-4 or GM-CSF was not beneficial.  
While cytokines were not required for MNGC formation using RAVD-THPs followed by Mtb 
infection, we determined that cytokine and chemokine secretion occurred from MNGCs. Interestingly, 
after an initial burst of cytokines (TNF-α, IL-6 and IL-10), RAVD-THPs showed a decline in the level 
of cytokines after Day 21 but switched to higher levels of chemokine secretion. Figure 11B illustrates 
that the altered secretion of cytokine-chemokines over 30 days of in vitro culture of MNGCs. 
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Table 3.  Replicate experiments in which M.tuberculosis infected, PMA or RAVD treated MNGCs 
were maintained in culture 
 
Experiments Duration for which MNGCs were 
maintained in vitro 
Studies performed
1-5 45 days Microscopy, CFU counts and cytokine-
chemokine analysis 
6-10 47 days CFU counts only
11-15 60 days Microscopy, CFU counts and cytokine-
chemokine analysis 
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Figure 9A.  PMA-THPS are unable to control infection with M. tuberculosis H37Rv.   
THPs activated with PMA were infected for 4 hrs with gfpH37Rv (MOI of 5), washed 3X then 
incubated for 10 days.  By Day 7, PMA-THPs showed robust intracellular growth of Mtb and by Day 
10, most of the macrophages died of uncontrolled bacterial growth. Viability was measured by using 
both trypan blue as well semi quantitative conversion of alamar blue vital dye in culture (data not 
shown).  
  
Day  1 Day  7
Day  10
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Figure 9B.  Unlike PMA-THPs, RAVD-THPS are able to control short and long-term infection 
with M. tuberculosis H37Rv.   
THPs were activated with either PMA (■)or RAVD (□), infected for 4 hrs (MOI of 1), washed three 
times to remove non-phagocytosed bacteria, incubated, then were lysed at intervals and plated for 
colony (CFU) counts (left panel) or treated with Alamar blue (right panel) to determine cell viability.  
Cell viability was measured in supernatants of replicate cultures containing alamar blue that was 
quantitated using emission at 590 nm in a fluorometer and expressed as AFUs (100 AFU=100% 
viability; 106 THPs well; dye conversion in 4 hrs).  Every week, from day 10, cultures were spiked with 
fresh, uninfected RAVD-THPs that eventually fused to the monolayer. By Day 10, most PMA-THPs 
died of uncontrolled bacterial growth and CFU counts were discontinued. However, replenishment of 
cells prolonged the survival of adherent Mtb infected RAVD-THPs, progressively showing morphology 
typical of multinucleated giant cells.   Microscopic images of morphological changes that correlated 
with CFU counts are indicated  next (Data representative of 5 separate experiments). 
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Figure 9C.  RAVD induces MNGC formation in M.tuberculosis infected THPs.   
RAVD-THPs were infected for 4 hrs (MOI of 1), washed to remove non-phagocytosed bacteria, and 
allowed to incubate.  Replenishment of RAVD, fresh medium and uninfected THPs every seven days to 
the cell culture was performed, then at intervals the cells observed under fluorescent microscopy. a) Day 
3-7, Top panel: Early stages in MNGC formation shown in THPs infected with gfpH37Rv (arrow) top 
panel; 485ex/530 em) Bottom panel: Nuclei were stained using Diamidinophenyl –indole (DAPI; 380 
nm ex/480 nm em) and the cell fusion triggered by  Mtb infected macrophage  is indicated by an arrow. 
The arrowhead shows the cytoplasmic veil. b) Days 7-20. Merged fluorescent images acquired at 485 
nm-ex/530 nm-em/380 nm-ex/480 nm-em. MNGCs shown over time with gfpH37Rv within cells 
(White bar= 5 µm). Data representative of 5 separate experiments.  
  
Day 3 to 7- Early event
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Figure 9D.  Electron microscopic (EM) analysis of multi-nucleated giant cell formation of THPs 
through treatment with RAVD.   
RAVD-THPs were infected for 4 hrs (MOI of 1), washed three times to remove non-phagocytosed 
bacteria, fixed in 0.2% glutaraldehyde, embedded, sectioned and examined a JEOL EM  after negative 
staining with uranyl acetate. Magnification indicated as inset. Left top and bottom: Images show that 
macrophages fuse with adjacent THPs through a zone represented by inter-digitating septae (broken 
arrow).  Top right: A single intact Mtb phagosome with tight membrane (white arrow) and bacterial 
debris in a phagosome (black arrow) in macrophages treated with RAVD are shown. Data representative 
of 5 separate experiments.  
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Figure 10.   Cell fusion in may involve ADAM-9  present between fusing RAVD-THPs. 
RAVD-THPs were infected for 4 hrs with unlabelled Mtb H37Rv (MOI of 1), washed three times and 
incubated. Every seven days replenishment of RAVD, fresh medium and uninfected THPs to the cell 
culture was performed. At intervals the cells were fixed, stained with Auramine for the detection of Mtb 
and probed with Texas Red fluorescent antibodies against ADAM-9.  On Day 28, 24 hrs after fresh 
addition of uninfected RAVD-THPS, adjacent cells show ADAM-9 present on their membranes. 
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Figure 11A.  Activation with RAVD but not cell fusion-inducing cytokines leads to long lived 
MNGCs containing M. tuberculosis. 
a.a.) Survival of Mtb infected THPs measured after treatment with either recombinant human IL-4 or 
GM-CSF or their combination with RAVD. Fluorescent conversion of the vital dye, Alamar blue, was 
used to monitor viability of THPs (100% viability=100AFUs from 24 well cultures measured at 485/530 
nm using Ascent fluoroscan). Only RAVD-THPs showed prolong survival measured up to 40 days in 
this experiment. Those treated with IL-4 or GM-CSF died because of excess growth of Mtb (not 
shown).  a.b.) RAVD cells of panel (a.a.) examined under phase contrast shows a MNGC (arrow) fusing 
with single THPs (arrowhead) on day 45.  a.c. & a.d.) Preformed (day 45) adherent MNGCs (pale 
green; white arrows) that contain multiple gfpH37Rv fuse with freshly added uninfected, 
carboxyfluorescein diacetate (CFSE) stained THPs (arrowheads) to form expanded MNGCs (bar= 5 
µM). a.e.) Phase contrast images of MNGCs on day 60 tend to show syncytium formation (bars= 5 
µM).  
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Figure 11B.  Cultured M. tuberculosis infected MNGCs exhibit biophasic cytokine and chemokine 
secretion. 
RAVD-THPs were infected for 4 hrs (MOI of 1), washed three times to remove non-phagocytosed 
bacteria, and allowed to incubate.  At intervals, supernatants from cell culture were measured for 
cytokines and chemokines using sandwich ELISA.  RAVD-THPs infected with H37Rv show increased 
cytokine (TNFα, IL6 and IL-10) secretion by Day 21 that decline to baseline level thereafter. 
Paradoxically, very little chemokines (MCP1, MIP1α and KC) are observed before day 14 (not shown) 
but they increase thereafter. Data from three separate experiments in which cytokine supernatants were 
examined and expressed as mean ± SEM.  
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DISCUSSION 
 
During our investigation into the effects of Retinoic acid and Vitamin A on THP maturation, we 
discovered that the intracellular growth of bacteria was decreased within RAVD-THPs compared to 
PMA-THPs.  The two activators also showed differential expression of receptors on their plasma 
membrane. One such up-regulated receptor, in RAVD-THPs, was macrophage mannose receptor 
(MMR).  This observation was interesting since MMR has been implicated during macrophage fusion 
events(71).  As vitamin D has also been shown to be involved in cell fusion events(159), we initiated 
studies to look at phenotypic changes in our RAVD-THPs infection model.  It has been suggested that 
giant cells occurring after cell fusion are better able to degrade intracellular debris and infection.  For 
example, cell fusion leads to osteoclasts that clears and remodels bone.  Giant cells occur typically at the 
center of granulomas.  Therefore, we began investigating the possibility of expanding our original 
concept of using RAVD as a better, more organic and physiological activator of THP cells, to 
determining if we could produce cell types that are commonly found in TB infections, specifically 
multi-nucleated giant cells (MNGCs).  
We discovered that continuous addition of fresh uninfected RAVD-THPs, every 7-10 days, to 
cultures of Mtb infected RAVD-THPs led to MNGCs that seemed to control mycobacterial infections.  
Although the MNGCs harbored mycobacteria, the pathogen did not grow uncontrollably and 
macrophage cell membrane integrity was maintained.  This was in contrast to PMA-THPs, which even 
after addition of freshly added uninfected THPs were unable to control intracellular Mtb growth 
eventually leading to cell death and failure to form MNGCs.  Higher concentrations (40 nM), PMA has 
been shown to induce cell fusion but only in human blood monocytes cultured for over 20 days(160).  It 
is possible that infection with Mtb allows for RAVD-THPs to live longer in culture, therefore allowing 
them to fuse to newly added non-infected RAVD-THPs.   
We also observed that RAVD-THPs that formed MNGCs produced copious cytokines at the 
beginning of the infection then increased in chemokine secretion suggesting that they are capable of 
recruiting and activating immune cells should they occur in vivo.  It would have been exciting to test 
this hypothesis using Dr. Canaday’s F9A6 antigen 85b recognizing humanized T-cells.  However, as 
previously stated, we would need to optimize the T-cell overlay assay before we could proceed. 
It is interesting to note that MNGC formation in culture has been shown to be dependent on the 
stage of monocyte to macrophage maturation.  Fully matured macrophages are unable to fuse and 
require addition of monocytes to form MNGCs(161).  This may explain our observation that cells 
treated with monocyte “maturation agents” such as IL-4 and GM-CSF did not exhibit as much MNGC 
formation as THPs treated with RAVD alone.  This leads to the idea that although RAVD-THPs express 
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a more mature surface receptor profile than PMA-THPs, they still retain a “monocyte-like” phenotype 
that allows for increased cell fusion.  As it still is not clear the mechanism of how monocyte cells fuse 
or what changes occur during monocyte maturation that inhibits cell fusion, our model could be a good 
tool to use to probe those interactions. 
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CHAPTER 6 
 
LONG TERM ACTIVATION OF MYCOBACTERIUM TUBERCULOSIS INFECTED  
MACROPHAGES WITH RAVD LEADS TO INCREASED PROTEASE ACTIVITY  
AND LYSOSOMAL LOCALIZATION WITH BACTERIA IN THP-1 MACROPHAGES 
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INTRODUCTION 
 
Phagosome Maturation 
Phagocytosis is a process that enables macrophages to clear out cell debris such as apoptotic 
cells and to eliminate pathogens. During the phagocytic process, bacterial ligands can bind to 
macrophages receptors that facilitate the plasma membrane to extend and engulf the pathogen to form a 
membrane bound structure called the phagosome.  Phagosomes can undergo a fairly rapid maturation 
process (5-15 min)(162) in order for its contents to be digested and degraded.  This is a sequential 
process that involves the maturation of the phagosome, where Rab5+ early phagosomes fuse with Rab7+ 
lysosomes to result in a phagolysosome.  Phagolysosome formation is marked by the acquisition of 
lysosome-associated membrane proteins (LAMPs) such as LAMP-1 and LAMP-3 (CD63) and 
generation of acidic proteases such as cathepsin D and G that are activated through vacuole 
acidification, in turn, mediated by membrane localization of vacuolar proton ATPase.  Mtb is a 
facultative intracellular parasite entering the host cell via phagocytosis.  In order for Mtb to survive, it 
has several evasion mechanisms that collectively lead to “phagosome maturation arrest.” In this process, 
that is a hall mark of Mtb, phagosomes containing bacteria avoid fusion with lysosome and prevent 
degradation. The maturation arrest is however a complex process in which Mtb evades fusion with 
lysosomes but fuses selectively with other endosomes and plasma membrane-derived fragments to allow 
intraphagosomal growth(163). A more controversial method that involves escape of Mtb from the 
phagosome into the macrophage cytosol has also been reported(164). 
 
Phagosomes in MNGCs 
 It is well documented that when macrophages fuse to form multi-nucleated giant cells (MNGC) 
they lose the ability to phagocytose extracellular material(165).  However, what is less clear is whether 
MNGCs can process their existing phagosomes into a matured phagolysosome and the precise 
localization of the phagosomes.  We have previously shown that RAVD-THPs infected with Mtb can 
induce better antimycobacterial processes such as ROS, RNS, autophagy and cathelicidin (Chapter 4).  
We therefore analyzed whether RAVD-induced MNGC formation would lead to an increase in 
phagosome maturation and therefore better control of intracellular Mtb growth. 
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RESULTS 
 
RAVD induces generation of active Cathepsin-D protease within the Mtb phagosomes of THP 
macrophages.  
Mtb was recoverable when THP lysates were plated on agar media until Day 30-35 (Figure 
9B).  However, after 28 days, frequently, THPs failed to yield CFUs on agar media even though they 
were clearly observable in lesser numbers within RAVD-THPs through microscopy. We speculated 
therefore that Mtb could avoid PL fusion to survive longer while Vitamin D3 may enhance P-L 
fusion(166). Thus, phagosomes of Mtb were fractionated using sucrose gradients from RAVD activated, 
Mtb infected THPs(95). The phagosome pellets and post-nuclear supernatant fractions were then probed 
with antibodies to Cathepsin-D (Cat-D) and lysosomal proteins indicative of PL fusion. Of these, Cat-D 
is a major protease that has been to be proteolytic for Mtb in acidic environments and targeted to their 
phagosomes(95).  Cat-D also generates peptide epitopes from Mtb proteins(167).  Cat-D breaks down 
from a 52 kDa immature inactive form to an enzymatically active 32 kDa form in an acidic pH. First, 
sucrose gradient purified phagosomes of Mtb were analyzed using western blot for Cat-D, an enzyme 
known to be targeted to Mtb phagosome(168).  Phagosomes of gfpH37Rv from RAVD-THPs contained 
the inactive Cat-D when they were examined 24 hrs after infection while by 48 to 72 hrs, active 
components of Cat-D appeared within the phagosomes (Figure 12A). Interestingly, at early times points 
(less than 7 days) Cat-G was absent in Mtb phagosomes harvested from RAVD THPs (not shown).  
  
RAVD induces Cat-D, Cat-G and lysosomal markers in THP macrophages that colocalize with 
Mtb phagosomes  
In the foregoing studies, we used western blot to document Cat-D since the active and inactive 
forms of Cat-D are only observable using blots and molecular weight standards(95).  As Mtb persisted 
in smaller numbers in MNGCs, over time, it became difficult to purify phagosomes in sufficient 
numbers using sucrose gradients. Therefore, immunofluorescence (IF) analysis was performed to 
localize Cathepsins and lysosomal markers using gfpH37Rv within MNGCs. This is an accepted 
procedure to determine lysosomal fusion of Mtb phagosomes. 
In addition to the well characterized Cat-D, Cat-G enzyme has been reported to be bactericidal 
for Mtb(169). Figure 12B illustrates that gfpH37Rv within RAVD-THPs stained for these markers 
suggesting that Mtb localized to protease rich compartments after RAVD activation. Finally, 
colocalization of phagosomes containing Mtb with lysosomal markers, LAMP1 and CD63, were also 
scored in RAVD-THPs.  CD63 is present in abundance in activated macrophages and is speculated to 
play a role in phagocytic and P-L fusion events(70).  It is a definitive marker of lysosomes. Likewise, 
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LAMP1 is involved in maintaining lysosome acidity and protecting the lysosomal membranes from 
autodigestion.  RAVD-THP phagosomes containing Mtb showed extensive colocalization with CD63 
and LAMP1, suggesting that after RAVD activation, internalized Mtb are located in lysosomal 
compartments (Figure 12C). In these two studies, we used inert latex bead controls to ensure that the 
antibodies also stained the latex beads after RAVD activation. Together, these studies strongly suggest 
that RAVD markedly enhances the localization of Mtb into protease rich compartments within THPs 
that are presumably degradative in nature.   
 
Long term activation with RAVD leads to MNGCs that contain persistent and virulent M. 
tuberculosis  
We noted an unusual observation that irrespective of the day of examination some gfpMtb 
remained completely unstained by either protease or lysosomal markers with THPs. Figure 12D 
illustrates such Mtb that are apparently viable since they maintain gfp- fluorescence even after 20 days 
in culture but do not stain with LAMP1, a phagolysosomal marker. We speculate that such Mtb were 
cytosolic and thus did not stain with membrane markers such as LAMP1.  
To further define the status of persistent Mtb, additional experiments were carried out.  THPs 
were cultured in 8 well slide chambers and at different time intervals, intracellular gfpMtb were scored 
per 100 macrophages and correlated to viable counts by plating whole cell lysates of replicate chamber 
THPs. Figure 13A illustrates that even when viable Mtb were not culturable on agar plates, gfpMtb 
were observable within THPs in slide chambers. Finally, THPs were tested over time for the expression 
of mRNA for antigen85B which is a specific marker for viability of Mtb.  Figure 13B shows that even 
when viable Mtb were not recovered from THPs on day 30, mRNA for antigen 85B was observed 
indicating that viable Mtb persisted within THPs. We therefore suggest that treatment of THPs with 
RAVD leads, over time, to a decline in the viability of Mtb and that some of bacteria appear to enter a 
persistent state. 
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Figure 12A.   Sucrose–gradient purified phagosomes of M. tuberculosis H37Rv from RAVD-THP 
are enriched with cathepsin-D.  
Phagosomes containing Mtb H37Rv were purified from RAVD-THPs at intervals as indicated using 
sucrose gradients. Phagosome pellets and phagosome free-post-nuclear supernatants (cytosol or PNS) 
were analyzed using Western blot using antibodies against Cathepsin-D (Cat-D), an aspartyl protease. 
This antibody detects the immature 52 kDa form as well as the mature 33 kDa form of Cat-D. Western 
blot shows that immature form of Cat-D at 24 hrs. and mature, active form at 48 hrs compared to the 
enrichment of Cat-D in the PNS. Bottom lane shows loading control β-actin. Western blot is 
representative of 4 separate similar experiments. 
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Figure 12B.  RAVD induce co-localization of M. tuberculosis gfpH37Rv with Cathepsin-D and 
Cathepsin-G proteases in THP macrophages.   
RAVD-THPs were infected with gfpH37Rv and stained for Cathepsin D (Cat-D; aspartyl protease) and 
Cathepsin G (Cat-G; serine protease) using specific antibodies and counterstained with Texas red 
labeled conjugates. Mtb phagosomes strongly colocalize with Cat-D and Cat-G after 21 days in culture.  
Approximately 75% of phagosomes containing gfpH37Rv stained for these markers. Inert latex beads 
also stain for these markers as they mature into lysosomes (not shown). Data from 5 separate 
experiments are summarized in the bar graph (± SD). 
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Figure 12C.  RAVD induces co-localization of M. tuberculosis gfpH37Rv with lysosomal markers, 
CD63 and LAMP-1 within THP macrophages.   
RAVD-THPs were infected with gfpH37Rv and stained for LAMP-1 and CD63 (LAMP-3) using 
specific antibodies and counterstained with Texas red labeled conjugates. RAVD-THPs stained strongly 
for the lysosomal markers CD63 and LAMP-1 after 21 days in culture.  Approximately 80% of 
phagosomes containing gfpH37Rv stained for these markers. Inert latex beads also stain for lysosomal 
markers as they mature into lysosomes rapidly (not shown). Data from 5 separate experiments are 
summarized in the bar graph (± SD).  
  
Merge
gfpH37Rv
CD63
Merge
LAMP1
gfpH37Rv
RAVD THPs
82 
 
 
 
 
 
 
Figure 12D.  Some M. tuberculosis gfpH37Rv phagosomes avoid labeling with LAMP1, a known 
marker for Mtb phagosomes.  
RAVD-THPs were infected with gfpH37Rv, maintained as MNGCs over 30 days in 8-well slide 
chambers and at intervals, stained for LAMP-1 and then counterstained with Texas red labeled 
conjugates. RAVD-THPs contained many gfpH37Rv that co-localized with LAMP-1 from day 7 
through day 20 (broken arrow) but some remain unstained (solid arrow). Data from one of 5 separate 
but similar experiments shown.  
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Figure 13A.  Mycobacterial growth cannot be consistently detected after 30 days in infected 
RAVD-THPs.  
RAVD-THPs were infected with gfpH37Rv and maintained as MNGCs over 30 days in 8-well slide 
chambers.  At intervals, gfpH37Rv were enumerated per 100 THPs through microscopy in triplicate 
chambers of slide culture and replicate chamber THPs were lysed and plated for CFUs as a whole to 
recover CFUs on 7H11 agar. RAVD-THPs with persisting Mtb showed no growth in agar plates by day 
30 (mean ± SEM of 3 experiments). 
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Figure 13B.  Mycobacterial growth cannot be consistently detected after 30 days in infected 
RAVD-THPs, but mRNA for Antigen 85B remain positive.    
RAVD-THPs were infected with Mtb H37Rv and maintained as MNGCs over 30 days in 24-well 
culture plates.  RAVD-THPs were analyzed at time intervals for mRNA specific for Antigen 85B of 
Mtb using RT-PCR.   Plated cell lysates and CFU counts were correlated with mRNA analysis.  On day 
30, mRNA messages were detected even when Mtb were not recoverable on agar media from lysates of 
THPs (mean ± SD of 3 experiments). 
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DISCUSSION 
 
 When we initiated this part of the study, we were interested in the ability of MNGCs to control 
intracellular MTB infection by permitting the Mtb phagosomes to fuse with the lysosomes. We found 
that MNGCs did permit more localization of Mtb phagosomes with lysosomes and that there was a 
progressive reduction in bacterial viability.  However, when we evaluated the persistence of 
mycobacteria within the MNGCs we were surprised to find that a small population of non-culturable 
bacteria was viable within the cells, emitting green fluorescence (gfpH37Rv) and producing mRNA for 
Antigen-85b, even after 30 days of culture. There are some genes of Mtb that are expressed more by 
bacteria entering into a latent phase. An example is the α-crystallin. However, our attempts at 
determining if Mtb were in a latent state by evaluating α-crystallin (acr) expression proved unproductive 
as we were unable to detect any mRNA for this antigen. However, we do believe that the bacteria are 
persistent in these cultures as mRNA for Antigen 85B indicates viable bacteria(170). Gene signatures 
associated with persistence and dormancy may allow us to develop better methods to detect amd treat 
latent tuberculosis in humans and RAVD THPs may provide a novel long term model to study 
persistence of Mtb.   
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DISCUSSION 
 
Monocytes and monocytoid cell lines generally express reduced numbers of receptors and are 
less efficient in phagocytosing pathogens(86). However, differentiated macrophages express abundant 
receptors, are more phagocytic and have enhanced intracellular mechanisms of bactericidal activity 
mediated by phagocyte oxidase (phox), inducible nitric oxide synthase (iNOS), increased targeting of 
proteolytic enzymes such as Cathepsins and enhanced phagosome-lysosome fusion(86). Monocyte to 
macrophage differentiation occurs after binding of pathogens to monocytes via their receptors in 
combination with the release of self-activating cytokines such as TNF-α, G-CSF and GM-CSF. 
Differentiation can be induced in vitro by phorbol esters(46), VD(47) and RA(48). However, following 
mycobacterial infection in vivo macrophages transform into Langhans type of MNGCs that are 
surrounded by immune cells of granulomas and contain Mtb thought to be non-replicating or dormant. 
Classic histological studies show that such bacilli reactivate to cause active infection while MNGCs can 
revert into macrophage phenotype and spread infection in rabbits and guinea pigs(171). To the best of 
our knowledge, an in vitro model of human macrophages that undergoes phenotypic changes closely 
associated with a transition between replicating Mtb into persistent Mtb has not been reported before. 
We suggest therefore that RAVD induced MNGC model is more similar to events that occur within 
humans. We observed that RA and VD were separately able to activate THPs although, maximal 
differentiation occurred in the presence of the two vitamins (Figure 1A-C, 2A-B; Table 1A-C, 2A). 
Subsequently, RAVD exerted more effective bactericidal effects compared to RA or VD alone (Figure 
5). These effects were due in part to the induction of NADPH oxidase (Figure 6A-E) although there 
was evidence that modest induction of iNOS also occurred (Figure 6E). Significantly, RAVD induced 
macrophage mediated killing of most Mtb organisms but few were left to survive within the 
macrophages that remarkably transformed into MNGCs (Figure 5, Figure 9B). Such MNGCs produced 
copious cytokines and chemokines (Figure 11B) suggesting that they are capable of recruiting and 
activating immune cells should they occur in vivo. This is the first report of the induction of long living 
MNGCs with Mtb infection using activation with physiologically compatible macrophage modulators 
such as RA and VD. Addition of cytokines such as GM-CSF and IL-4 did not markedly alter the RAVD 
induced transformation of MNGCs (Figure 11A-a.a.). This suggested that RA and VD3 mediated 
biochemical processes separate from those induced by the cytokines. 
The induction of MNGCs by RAVD correlated and clarified previously reported observations. 
VD was found to enhance DC-SIGN levels in THPs earlier (Figure 1D) and the well documented role 
of DC-SIGN in mycobacterial recognition confirmed the increased efficacy of RAVD-THPs during 
phagocytosis (Figure 3). Likewise, increased expression of Mannose receptor (MMR) in RAVD-THPs 
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(Figure 2B) correlated with the finding that inhibition of MMR prevented MNGC formation(172).  
Clearly, RAVD transformed THPs and we suggest that, by inference, they regulate differentiation of 
human monocytes to a more efficient macrophage phenotype. 
The bactericidal function of RAVD in THPs was partly due to the induction of ROS since the 
ROS inhibitor DPI enhanced survival of Mtb (Figure 6E).  Although other pathways cannot be ruled 
out, this was similar to the previously reported induction of ROS by RA(128).  Recently, a study 
showed that Vitamin D3 alone can induce autophagosome formation to kill internalized Mtb(123).  
Knock-down of beclin-1, a key protein involved in targeting vesicles for autophagy, demonstrated that 
RAVD can also activate autophagy in order to keep intracellular Mtb growth in check (Figure 7B).   It 
should be noted here that we tested the dual effects of RAVD, whereas the individual effects of RA and 
VD were measured in cells with slightly different phenotype in earlier studies. RA and VD are ingested 
by humans together and we further propose that it is the dual effect of RA and VD that is likely to be 
important in vivo. 
Our initial studies indicated that inhibition of iNOS with NMMA enhanced the survival of 
intracellular Mtb in RAVD-THPs (Figure 6E) although, curiously, we did not find significant levels of 
nitrate, an indicator of NO synthesis in the medium. It is possible that NO is induced but at such low 
levels not detectable by Greiss reagent. VD has been reported to induce iNOS in murine and human 
macrophages(126) and it remains to be determined whether it does induce sustained iNOS in THPs.  
Among the spectrum of effects of RAVD on THPs, we observed a striking change in the 
morphology that led to the formation of MNGCs containing persistent Mtb (Figure 9C). Since 
persistence of Mtb in humans is the leading cause of reactivation tuberculosis, these findings need 
additional elaboration. Neither RA nor VD alone led to long living THP derived MNGCs but their 
combination was very effective. Since VD induced or suppressed giant cell formation depending upon 
the cell phenotype and RA only transformed trophoblasts and osteoclasts(173), we propose that their 
combination is more effective in inducing MNGC formation in THPs. In addition, we found that RAVD 
induced cell fusion through the induction of the matrix metalloproteinase (ADAM-9) that was 
detectable only as a transient staining between the cell junctions (Figure 10). Finally, RAVD induced 
MNGCs could be kept in vitro for observation for over 60 days yielding the longest living giant cell 
phenotype in culture. 
A more interesting observation was the persistence of Mtb in MNGCs in a non-replicating stage 
for as long as 60 days in vitro. First, microscopy showed more fluorescent-Mtb per MNGC than 
recoverable colony counts from lysates of MNGCs (Figure 13A). Second, MNGCs positive for gfpMtb 
but negative for CFU growth on plate media still expressed mRNA for Antigen-85B which is a marker 
for viable Mtb (Figure 13B). This was reminiscent of our previous observation that persistent, non 
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replicating Mtb in mice treated with antibiotics still expressed abundant mRNA for Antigen 85B. These 
studies together indicate that RAVD eliminate most replicating Mtb through inducing bactericidal 
functions but few surviving Mtb are driven into a non-replicating persistence. Thus, we successfully 
developed a novel macrophage model to study the long term persistence of Mtb. The availability of a 
cell culture model that reflects the natural niche for Mtb in vivo is important from several directions. It 
may be possible to study the dynamics of persistence over time and devise methods to eliminate 
persistent Mtb. Analysis of MNGCs may reveal mechanisms that keep replicating Mtb contained and 
unable to spread disease. Preliminary studies were performed to neutralize both ROS and NO in 
MNGCs to determine whether persistent Mtb could be revived with unsuccessful results. However, we 
propose that reactivation of Mtb within macrophages is dependent upon multiple, perhaps time-
dependent, factors that need to be carefully dissected out. These include the blockade of multiple 
mechanisms of bactericidal activity and cytokine mediated modulation of MNGCs in conjunction with 
stimulation of intracellular Mtb through growth stimulatory ‘quorum sensing factors’. The availability 
of persistent Mtb within a macrophage niche is an attractive model to address these issues.  
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Materials and Methods 
 
Activation of THPs and mycobacteria. Human THP-1 monocytoid cell line  (TIB#3456, ATCC, MD) 
was maintained at 37oC and 5% CO2 in Hepes buffered RPMI-1640 (Sigma Aldrich, St. Louis, MO) 
medium with 10% heat inactivated FBS, 50 µg/mL gentamicin and 100U /mL penicillin /mL (pH 7.2). 
THPs were genotyped by ATCC to exclude contamination with other cell lines. Cells were passed so 
that cell counts did not exceed 106/mL. When needed, cells were expanded into 75 mL flasks and were 
activated with retinoic acid (1 μM) and vitamin D3 (1 μM) or phorbol myristyl acetate (10 ng/mL = 16 
nM; all from Sigma Aldrich, St Louis MO) for 3 days.   RAVD concentrations were selected based on 
the physiological levels that occur in the fluids of humans(174, 175). It is noted here that the 
cholecalciferol version of Vitamin D was used in this study. Vitamin D is predominantly metabolised to 
1,25 Dyhydroxyvitamin D3 in the liver and kidneys. However, during infection, macrophages and 
dendritic cells have been shown to metabolize cholecalciferol for use in their antimicrobial 
processes(10). Mycobacterium tuberculosis (Mtb) H37Rv were obtained from ATCC repository and 
gfp- strains of Mtb were prepared as described before (176). They were cultured in 7H9 broth with (gfp 
expressing Mtb H37Rv or Mtb H37Ra strains) or without (Mtb H37Rv and Mtb H37Ra) 25 µg/mL 
kanamycin for 10 days and highly viable suspension aliquots frozen stored at -80oC.  
 
Surface receptor analysis. Cells were activated for 3 days using varying doses of PMA (1, 10 and 50 
ng/mL) and RAVD (10, 100 and 1000 nM) and infected with H37Rv for 24 hrs.  The infected cells were 
washed once with PBS, Fc blocked and stained, on ice for 30 min, with  FITC or PE conjugated anti-
CD1d, CD14, CD44, CD80, CD86, CD184, CD195, DC-SIGN and HLA-DR (all from BD Pharmingen, 
San Jose, CA) antibodies. The cells were post-fixed with 2.7% paraformaldehyde before analysis in BD 
Facscan. PMA and RAVD activated and infected THPs were analyzed for mannose receptor expression 
by incubation with FITC-tagged mannosylated MBSA (FITC-MBSA) (Sigma Aldrich, St Louis MO) 
for 30 min at 37oC after which the cells were washed and fixed for cytometric analysis (177). In this 
assay, uptake of into THPs was performed incubated at both 4oC and 37oC. At, 4oC minimal uptake 
occurs compared to active uptake at 37oC.  
 
Infection of THPs with Mtb and short term growth curves. Mtb suspensions were subjected to 
gentle sonication at 4 watts, matched to McFarland standard #1 and spun at 500 rpm for 2 mins. The 
supernatant contained single colony forming unit (CFU) of Mtb without clumps and were used for 
infection. Activated THP cells were infected with an MOI of 1-10 with Mtb for 4-24 hrs at 37oC and 5% 
CO2 with gentle mixing to ensure uniform infection. Cells were washed three times with sterile medium 
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to remove non-phagocytosed bacteria, counted and dispensed to 24-well plates (CFU counts, MNGC 
cultures) or 8-well chamber slides (Mtb uptake, immunostains) at 106 cells/mL medium containing 
antibiotics (50 µg/mL gentamicin and 100U /mL penicillin /mL) in replicates. For growth curves 
between days 1-10, cells from 24-well plates were aspirated, pelleted, and lysed in 0.05% SDS within 
the same well thus accounting for adherent as well as some floating macrophages. When macrophages 
were adherent both floater cells as well as adherent macrophages were pooled for preparing lysates, 
which were then were plated at ten-fold dilutions on 7H11 agar (Remel, Lenexa, KS) for colony 
forming unit (CFU) counts. PMA-THPs generally die between days 7-10 due to an excess growth of 
Mtb while RAVD-THPs control growth of Mtb and cells remain viable. Viability of THPs during Mtb 
infection was determined by adding 10% by volume of alamar blue vital stain that turns pink within 4 
hrs when macrophages are fully viable. The dye conversion was quantitated using an Asecent 
fluorometer; it is also readable using an ELISA reader (Invitrogen, USA). 
 
Growth and maintenance in slide chambers: Cells plated onto 8-well chamber slides (Permanox 
plastic chamber slides, Nalge Nunc International, Rochester, NY), became adherent after Mtb infection 
and were fixed either with absolute alcohol for Ziehl-Neelsen stain and scored by microscopy for Mtb 
uptake into the macrophages or with 2.7% paraformaldehyde for immunostaining with antibodies. THPs 
in slide chambers were kept alive for several weeks or months with medium replenishment as described 
below.  
 
Long term cultures of THPs and induction of Multi-Nucleated Giant Cells (MNGCs). THPs 
infected with Mtb as above for short term infection were continued into long term cultures of MNGCs 
as follows. Only RAVD-THPs were viable beyond 10 days of Mtb infection. On day 3 post infection, 
when RAVD-THPs begin to adhere to 24-well plates, cells were aspirated and fresh culture media 
containing RAVD (1 μM) and antibiotics (50 µg/mL gentamicin and 100U /mL penicillin /mL) were 
added to the culture plates.  On day 10, when the cells had differentiated and most adhered to the plastic 
surface, fresh media with RAVD supplement was added along with freshly activated but uninfected 
RAVD-THP cells to a final concentration not exceeding 106cells/mL. Thus, the only time Mtb was 
added to long term cultures of THPs was during an initial infection. Thereafter, fresh media 
supplemented with RAVD was added every 3 days and freshly activated cells every 7 days.  Pre-formed 
giant cells on monolayers fused with freshly added THP cells yielding increasingly larger MNGC.  
Control cultures of THP-1 cells activated with RAVD and without Mtb infection did not survive beyond 
10 days. a) Growth curve of Mtb. During long term infection lasting 10-60 days, Mtb infected THPs 
were adherent but some floaters were present. Thus, during this time interval cells were aspirated, 
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pelleted and lysed along with adherent cells on monolayers to determine CFU counts. b) Cell fusion to 
expand MNGCs: To demonstrate cell fusion, preformed MNGCs adherent to tissue culture wells were 
added with Carboxyfluorescein diacetate (CFSE; Molecular Probes, Eugene OR) stained, RAVD-THPs. 
Cells were stained with CFSE as per manufacterer’s instructions.  Cell fusion was visible between 
MNGCs fusing with CFSE stained single THPs. c) Cytokine effects: RAVD and cytokines were 
compared for their ability to induce MNGCs by infecting THPs with Mtb and addition of either RAVD 
or  recombinant human IL-4 and GM-CSF separately or in combination (R & D Sciences; 20 ng/ml/106 
macrophages each). THPs were re-incubated with fresh IL-4 or GM-CSF, replenished daily. To 
determine synergistic effects, RAVD- THPs were also added with the cytokines. d) Viability analysis: 
Alamar blue was used as vital stain to determine viability of MNGCs. e). Cytokines and chemokine 
secretion from MNGCs:  Cytokines and chemokines secreted from MNGCs were quantitated using 
sandwich ELISA with paired antibodies (R & D Sciences, USA). Long term cultures for MNGCs were 
performed over 20 times with reproducible results within a 2 year time frame. d) Phagosome analysis 
for proteases. Mtb phagosomes were purified from RAVD-THPs on day 12 using sucrose gradients and 
analyzed for Cathepsin-D using western blot.  These methods have been optimized in our laboratory(95) 
(178) (179).  
 
Phagosome Isolation.  For the isolation of Mtb-containing phagosomes, macrophages were infected as 
previously described.  Phagosomes were fractionated as per the procedures described by Ullrich et 
al.(180, 181) Briefly, as per our modified protocol, macrophages were scraped, washed three times in 
fractionation buffer (PFB) with 10mM HEPES, 5 mM EDTA, 5 mM EGTA (pH 7.0), and suspended in 
PFB with homogenization buffer (25 mM Tris-HCl (pH 7.4), 0.25 M sucrose, 2.5 mM dithiothreitol 
(DTT), 2.5 mM EDTA, and the following inhibitors: 5 mM benzamidine, 50 μg/ml leupeptin, 50 μg/ml 
aprotinin, 50 μg/ml trypsin inhibitor, 5 μg/ml pepstatin, 1 mM PMSF, and 20 mM NaF).  Pellets were 
then homogenized in a glass tissue homogenizer 10 times and passed 10 times through a 28-gauge 
needle. Lysates were centrifuged at 500 x g for 5 min to sediment nuclei and the postnuclear supernatant 
was layered on a step gradient of 50% and 12% sucrose in PFB. After centrifugation at 1000 x g for 60 
min, the interphase of phagosome fraction was collected and further purified by passing through two 
successive cushions of 70- and 400-kDa Ficoll in PFB as described before. The final purified 
phagosomal pellet was collected by centrifugation at 10,000 x g for 15 min and suspended in SDS 
sample buffer for use in Western Blot analysis. 
 
Antigen processing and presentation assays. THP-1 or human MonoMac macrophages cell lines were 
cultured in 25mL flasks infected with either H37Rv or BCG-14 at an MOI of 10.  After infection, the 
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cells were aliquoted into microcentrifuge tubes (1.5 x105 cells/tube) and washed by centrifugation three 
times to remove any non-phagocytosed bacteria.  Antigen 85b (F9A6) or α-crystallin (5MB) specific T-
cell hybridoma cells (graciously donated by Dr. David Canaday) were pelleted and resuspended in 0.5 
mL of DMEM. T-cell hybridoma cells were combined with infected THPs or MonoMac cells and 
allowed to incubated for the specified times.  Supernantants were collected at 4 or 24 hrs and analyzed 
using ELISA for IL-2 production. 
 
Immunofluorescent Labeling. Activated THPs infected with gfpH37Rv were grown in an 8-well 
chamber slides were washed once with PBS, fixed in 2.7% paraformaldehyde and permeabilized for 30 
min with a staining buffer containing 1% saponin, 0.1% glycine, and 2% heat-inactivated autologous 
human serum in PBS.  The slides were washed and stained overnight at 4ºC with 1/250 dilution of 
antibodies against p47/67phox, CD63, LAMP-1, Cathepsin-D and Cathepsin-G. Antibody dilutions were 
arrived at using preliminary dose-titrations. The slides were washed three times with staining buffer and 
then a 1:2500 dilution of the appropriate secondary Texas-Red conjugated antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) was added and incubated at room temperature for one hour. After 
further washing, the slides were mounted in Fluorsave (Calbiochem, Gibbstown, NJ) with or without 
DAPI stain and examined using a Nikon fluorescence microscope equipped with deconvolution 
software followed by analysis in a laser confocal microscope.  Negative controls consisted of naïve 
THPs (no activation) and uninfected activated THPs. In addition, isotype controls used were gfpH37Rv 
infected cells stained with normal goat or mouse IgG followed by a secondary antibody conjugated with 
Texas Red.  All uninfected and unactivated THPs presented a uniform low background fluorescence 
using this procedure. Phagosomes staining for distinct antibodies were scored for colocalization as 
described before in our previous studies using mouse macrophages(124). For colocalization 
experiments, bacteria of over 100 macrophages in each chamber of triplicate well slides were counted 
and averaged for three separate experiments. The colocalization percentage was plotted and Student’s t 
test was used to determine significance between the groups.  
 
Detection of Reactive Oxygen Species (ROS) and Nitric Oxide. Activated THPs were treated with 
2,7-Dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen, Carlsbad CA) as per the 
manufacturer’s instructions to measure internal ROS production in pre and post Mtb infected 
macrophages. Basal levels of ROS in activated THPs were analyzed for a three day period by flow 
cytometry.  Mtb infected cells were incubated for 5 days and tested for intracellular fluorescence as 
above using fluorometry (Ascent Fluoroscan) instead of flow cytometry because of contamination issues 
and infectious risk with virulent Mtb.  The specificity of ROS mediated conversion of DCF was 
95 
 
confirmed by using the ROS inhibitor, 10mM diphenyleneiodonium (DPI; Sigma Aldrich, St. Louis, 
MO). The contribution of inducible nitric oxide synthase (iNOS) to the killing of internalized Mtb was 
determined by the addition of 10 μM of N(G) -monomethyl-l-arginine (L-NMMA; Alexis Biochemicals, 
San Diego, CA; an inhibitor of nitric oxide response) to the cultures and the supernatants were titrated  
using diaminonapthalene (DAN) fluorescent dye and Ascent Fluoroscan instrument.  
 
siRNA Knock-down of Beclin-1 to determine induction of autophagy. THP-1 cells were seeded 
2x106 cells per well onto a 6-well plate and rested for 24 hrs in media without antibiotics.  They were 
then activated with RAVD as above and three days later, the knock-down of beclin-1 was performed as 
per manufacturer’s instructions (Lonza AG, Walkersville MD) where the beclin-1 siRNA (Sigma 
Aldrich, St Loius MO) was nucleofected into the cells and allowed to rest for 24 hrs.  Infection with 
Mtb was then performed for 4 hrs, washed cells were re-incubated and lysates of macrophages were 
plated for CFU counts of Mtb. Just before infection, western blot analysis with an antibody to beclin1 
(Santa Cruz Biotechnology, USA) was conducted to determine knock-down. The fluid phase 
autophagosome marker monodansyl-cadaverine (MDC) was used to label Mtb phagosomes of  beclin1 
knockdown  and control THPs as described before(116). 
 
Western blot Analysis.  Whole cell lysates or phagosome fractionations were collected then heated at 
98°C for 5 min.  Samples were electrophoresed using either 7–15% or 10-15% gradient SDS gel, 
electroblotted and membranes were probed with cathepsins, autophagy etc.  Bands were visualized 
using an ECL chemiluminescence kit from Amersham Biosciences. 
 
Electron Microscopy. Infected RAVD activated THP cells were prepared for examination by 
transmission electron microscopy.  After the indicated incubation periods, the glutaraldehyde-fixed (2% 
in PBS, pH 7.6) cells were washed in Millonig’s buffer, post-fixed in 50/50 osmium 
tetroxide/Millonig’s, dehydrated through graded ethanol solutions and embedded in 50/50 LX-112 
resin/propylene oxide. 500nm sections are cut from each block using a glass knife on a Leica Ultracut R 
microtome and stained with 0.5% Toluidine Blue.  The blocks were trimmed and thin sections (80nm & 
100nm) are cut using a DiATOME diamond knife, one each of the two thicknesses are floated on either 
100 or 150 mesh copper grids (Electron Microscopy Sciences) and heat fixed in a 70°C oven for at least 
one hour. The grids are stained for 15 mins using 2% uranyl acetate, rinsed with double distilled water, 
stained 5 mins in Renold's lead citrate, rinsed and dried in a 70oC oven.  The specimen grids are imaged 
in a JEOL 1200 transmission electron microscope at 60kV with digital images collected using a 1k X 1k 
Gatan BioScan camera, Model 792. 
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Analysis of persisting and non-replicating Mtb in THPs. RAVD-THPs were activated and infected 
with gfpH37Rv as above and maintained as MNGCs in 8 well slide chambers or 24 well TC plates up to 
30 days or more. At time intervals- a) THPs of the 8 well slide chambers in triplicates were lysed with 
200 µL per chamber of 0.01% SDS and the entire lysate was plated on 7H11 agar plates for CFUs 
expressed per 106 macrophages, b) replicate chambers macrophages were washed at the same time, 
fixed and examined for gfpH37Rv through microscopic evaluation and expressed as number of Mtb per 
100 macrophages per chamber in triplicates, and c) THPs in parallel cultures  of 24 well plates were 
lysed with RNAzol and mRNA obtained was analyzed using real-time PCR as described  using the 
following primers for antigen 85B(170, 182). The primers were; Forward primer: 5’- 
TCAGGGGATGGGGCCTAGCC-3’ Reverse primer:  5’- GCTTGGGGATCTGCTGCGTA-3’ RT 
primer: 5’- GCCGGCGCCTAACGAACTCTGC-3’ Taqman Probe: 85B-TP 5’-FAM-
TCGAGTGACCCGGCATGGGAGCGT-BHQ-1 – 3’.  Fold-expression of mRNA from macrophage 
lysates was compared to mRNA messages from a 7 day viable culture of Mtb that was adjusted to 
contain 106 CFU/mL diluted from a suspension matched to McFarland #1 turbidity standard (108 
CFU/mL).   
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